ArticlePDF Available

Role of Nanomedicine for Targeted Drug Delivery in Livestock: Future Prospective

November 2023

November 2023
12

DOI:10.2174/0122117385267911231109184511

Authors:

Aarti Ahlawat

Guru Jambheshwar University of Science & Technology

Dr Md Sabir Alam

SGT College of Pharmacy, SGT University, Gurgaon, Haryana

Show all 5 authorsHide

Nanotechnology has advanced significantly in recent years and is currently used in a wide range of sectors. Only a handful of the many diverse issues covered by nanotechnology include nanoscale gadgets, nanomaterials, nanoparticles, and nanomedicines. Its performance in treating a range of grave conditions, such as cancer, early detection of infections, analysis, bio-imaging, and bio sensing, suggests that it is highly advanced. Nanoscale materials have been employed for medicine delivery, pharmaceutics, and a range of diagnostic techniques due to their various biochemical and physical features. The use of nanoparticles that are based on nanotechnology can significantly improve the drug delivery mechanism. It is believed that nanoparticles capacity to improve the stability and solubility of drugs and shield them from impulsive inactivation during drug transfer makes it possible for them to capture, encapsulate, or bond with the molecules. The use of nanomedicine or nanoparticle-based tactics to combat viruses has emerged as a potentially life-saving tactic. These approaches have the power to protect both humans and animals against viruses. In order to inactivate a virus, nanoparticles have the unique capacity to connect with the virus epitope. Many nanocarriers have the potential to replace current drug delivery methods with focused drug delivery. Small dosages, low toxicity, and targeted flow of drug release at the infected location are all characteristics of nanocarriers or nanomedicine. Due to their distinct physicochemical and biological features, nanomaterial-based drug delivery systems (NBDDS) are frequently employed to enhance the safety and therapeutic efficacy of encapsulated pharmaceuticals. The program’s objective can be supported by the applications that have so far been developed. This idea is therefore essential and sophisticated for the development of civilization. Our research will therefore concentrate on how human use of nanomedicines has changed through time in many domains.

Nano careers fight against cancer. (A higher resolution/colour version of this figure is available in the electronic copy of the article).

…

Role of Nanoparticles for Bioimaging

…

Role of Nanotechnology for Neurological.

…

Figures - uploaded by Dr Md Sabir Alam

Content may be subject to copyright.

Content uploaded by Dr Md Sabir Alam

Content may be subject to copyright.

Send Orders for Reprints to reprints@benthamscience.net

Pharmaceutical Nanotechnology, xxxx, xx, x-x 1

REVIEW ARTICLE

2211-7385/xx $65.00+.00 © xxxx Bentham Science Publishers

Role of Nanomedicine for Targeted Drug Delivery in Livestock: Future

Prospective

Neeti Hooda1, Aarti Ahlawat1, Puja Kumari2, Md. Sabir Alam2 and Jamilur R. Ansari3,*

1Department of Chemistry, P.D.M. University, Bahadurgarh, Haryana, 124001, India; 2SGT College of Pharmacy, SGT

University, Gurgaon-Badli Road Chandu, Budhera, Gurugram, Haryana, 122505, India; 3Functional Packaging Materi-

als Lab, Department of Packaging, School of Science and Technology, Yonsei University, 1 Yonseidae-gil, Wonju-si,

Gangwon-do, 26493, Republic of Korea

Abstract: Nanotechnology has advanced significantly in recent years and is currently used in a wide

range of sectors. Only a handful of the many diverse issues covered by nanotechnology include na-

noscale gadgets, nanomaterials, nanoparticles, and nanomedicines. Its performance in treating a range

of grave conditions, such as cancer, early detection of infections, analysis, bio-imaging, and bio sens-

ing, suggests that it is highly advanced. Nanoscale materials have been employed for medicine deliv-

ery, pharmaceutics, and a range of diagnostic techniques due to their various biochemical and physical

features. The use of nanoparticles that are based on nanotechnology can significantly improve the drug

delivery mechanism. It is believed that nanoparticles capacity to improve the stability and solubility

of drugs and shield them from impulsive inactivation during drug transfer makes it possible for them

to capture, encapsulate, or bond with the molecules. The use of nanomedicine or nanoparticle-based

tactics to combat viruses has emerged as a potentially life-saving tactic. These approaches have the

power to protect both humans and animals against viruses. In order to inactivate a virus, nanoparticles

have the unique capacity to connect with the virus epitope. Many nanocarriers have the potential to

replace current drug delivery methods with focused drug delivery. Small dosages, low toxicity, and

targeted flow of drug release at the infected location are all characteristics of nanocarriers or nano-

medicine. Due to their distinct physicochemical and biological features, nanomaterial-based drug de-

livery systems (NBDDS) are frequently employed to enhance the safety and therapeutic efficacy of

encapsulated pharmaceuticals. The program’s objective can be supported by the applications that have

so far been developed. This idea is therefore essential and sophisticated for the development of civili-

zation. Our research will therefore concentrate on how human use of nanomedicines has changed

through time in many domains.

A R T I C L E H I S T O R Y

Received: July 24, 2023

Revised: ?????? ??, 202?

Accepted: October 03, 2023

DOI:

10.2174/0122117385267911231109184511

Keywords: Clinical efficacy, drug delivery, magnetic nanoparticles, nanomedicine, quantum dots.

1. INTRODUCTION

Nanoscience is the study of materials or resources that are

very small, or nanoscale. Nanotechnology is the process of

improving or completely changing materials at the nanoscale

scale. The consumption of nanoparticles with a diameter of

100 nm or smaller in various goods is rising. Innovative nan-

otherapeutic designs are made possible by nanotechnology for

a variety of reparative and investigative uses [1-2]. Thus, na-

nomedicine [3] is a quickly developing interdisciplinary sub-

ject where medical practices are combined with nanotechnol-

ogy methods to provide complex medical care based on mo-

lecular understanding. Nanoscale drug delivery systems offer

a platform for enhancing pharmacology and also boost the

bio-distribution of treatments to the target organs,

Address correspondence to this author at the Department of

Packaging, School of Science and Technology, Yonsei University, 1

Yonseidae-gil, Wonju-si, Gangwon-do, 26493, Republic of Korea;

Tel: +82 10-4008-0786; E-mail: drjransari@yonsei.ac.kr

leading to increased effectiveness as drug toxicity is con-

strained. These strategies have revolutionized medication de-

livery methods and taken advantage of them for therapeutic

applications. To aid in drug distribution, various nanomedi-

cines have been proposed [4].

Due to the enhanced solubility, diffusion, blood circula-

tion, and bioavailability of different medications, nanotech-

nology-based approaches have several uses in the medical in-

dustry. Because of their regulated and decreased immunegen-

esis, nanotechnology platforms have made treatments possi-

ble in a wide range of contexts. Additionally, nanotechnology

has given the medical professions more advantageous and di-

verse pathways, multi-functionality, lower toxicity, and

lengthy life cycles [5]. The compensation for nanotechnology

is bridged in terms of occurrence, dosage, and toxicity. Future

medical advancement depends on evaluating the causal fac-

tors, such as the size, functioning, and chemical makeup of

nanoparticle liberation systems. Future developments in na-

2 Pharmaceutical Nanotechnology, xxxx, Vol. x, No. x Hooda et al.

nomedicine include the development of drug delivery meth-

ods, DNA sequencing, and the use of nanomaterials in sci-

entific research [6]. Nanomedicine drugs are prone to a num-

ber of restrictions that lead to poor absorption and drug re-

sistance because to anatomical, elemental, physiological,

and other related barriers. Due to their small size, nanoparti-

cles can penetrate human cells through microscopic capillar-

ies [7, 8]. These nanoparticles can lessen drug toxicity and

resistance while increasing its solubility. Additionally, the

degree of susceptibility of nanomaterials when employed for

medicinal purposes increases along with their level of devel-

opment. Due of this increased likelihood of interacting with

body fluids like human blood, nanomaterials are more likely

to be harmful to human health [9, 10]. Nanomedicine entails

the examination, therapy, oversight, and administra-tion of

numerous tissue-related groups. Nanomedicine offers a

workable method for boosting scientific discoveries through

the improvement of therapeutic efficacy and enhanced liber-

ation to infectious areas for melanoma therapy [11]. With the

prevalence of diseases rising so quickly, it is more important

than ever to prepare future students for careers in the field of

nanomedicine. In this section, we’ll give a quick overview

of a variety of smart carriers for the administration of medi-

cation, including polymers, liposomes, organic-inorganic

hybrid nanoparticles, exosomes, and other nanomaterials

[12]. The biomedical and therapeutic applications of con-

trolled drug delivery nanoplatforms as well as the difficulties

such nanoplatforms faced in clinical translation have also

been highlighted [13]. A potent statistical method for varia-

ble screening and optimization is the design of experiment

(DoE). It is based on the simultaneous adjustment of several

variables with the goal of identifying the parameter config-

uration that maximizes one or more desired outputs while

requiring the fewest possible experimental runs, resulting in

a very cost- and time-effective method. DoE is still only

slightly utilized in the field of nanomedicine, and frequently

its logical application and analysis result are difficult to un-

derstand by many. Despite the substantial opportunity for in-

novation and process improvem-ent that this strategy offers

[14].

In addition, recent studies have revealed that natural iron

oxide magnetic nanoparticles produced as a result of bio-

mineralization processes make up the majority of living mat-

ter, including everything from bacteria to people. The most

prevalent magnetic nanoparticles in both living and non-liv-

ing nature are known to be magnetite (Fe3O4) and maghemite

(Fe2O3). These nanoparticles can be found using paramag-

netic centers that were discovered using the EPR approach

in natural systems [15]. A powerful antibacterial agent that

may be employed in a variety of nanostructured materials of

different shapes and sizes is silver, which has developed

over time. Antimicrobial compounds based on silver nano-

particles (AgNP) are used in a variety of applications, in-

cluding medicine, coatings and surface treatment, the chem-

ical and food industries, and agricultural productivity. The

size, shape, and surface area of AgNPs are all significant

structural factors to take into account when developing for-

mulations for particular applications. AgNPs of different

sizes and shapes that are less hazardous have been cre-

ated using various techniques [16]. Investigated are the ef-

fects of extract concentration, contact time, pH, and temper-

ature on the Ag NPs reaction rate and form. The data showed

that as the temperature rose in the basic medium, the rate of

AgNPs creation increased dramatically. By using the well

diffusion method, the antibacterial potential of produced

AgNPs was contrasted with that of aqueous OLE. With re-

gard to multidrug resistant Staphylococcus aureus (S. au-

reus), Pseudomonas aeruginosa (P. aeruginosa), and Esche-

richia coli (E. coli), the AgNPs varied concentration effec-

tively suppressed bacterial growth. The application of nano-

technology in medicine is one of the largest. Nanoparticles

must be in ecologically sound forms for such extensive de-

ployment. It was shown that nanoparticles could result in

some harmful effects building up in the human body. As a

result, it is essential to obtain environmentally sound nano-

particles that may be used to create nanomedicines. The sil-

ver nanoparticles (AgNPs), with their distinctive features

and significant practical value, are growing in popularity in

modern medicine. The strong surface reactivity (such as ab-

sorption and catalysis) produced by AgNPs high surface en-

ergy makes them suitable for use in medication delivery

[17]. Therefore, oral administration would continue to rule

the drug delivery research and pharmaceutical industry, re-

gardless of historical development, technological advance-

ments, market occupancy, or management advantages. Due

to the strict physiological barriers in the GI tract, which in-

clude acid or enzymatic degradation, extreme pH-induced

inactivation, and poor intestinal barrier penetration, many

oral drugs, including peptides, proteins, antibodies, and nu-

cleic acids, frequently encounter problems. This signifi-

cantly reduces bioavailability [18].

2. TYPES OF THE NANOPARTICLES DRUG DELIV-

ERY SYSTEMS (NDDSS)

The term “nanoparticles drug delivery systems” (NDDSs)

refers to substances or resources with a nanometer-scale or

made up of fundamental units in three dimensions [19, 20].

For the purpose of enhancing drug delivery, these technolo-

gies have significantly advanced the pharmacy and biomedi-

cal fields [21]. According to the materials' composition, nano-

materials utilized in nanoparticle drug delivery systems can be

divided into a variety of categories. The main problems of

conventional medication treatment, such as inadequate stabil-

ity and solubility, lack of transmembrane transport, brief cir-

culation duration, and adverse toxic effects, were removed by

combining therapeutic medicines with nanoparticles using

logical targeting pathways. According to the taxonomy of

nanotechnology, they can be divided into three categories: in-

organic (gold, ferric oxides, quantum dots, lanthanides, etc.),

organic (micelles, liposomes, dendrimers, etc.), and biological

(exosomes, lipoproteins, ferritin, etc.). According to the clas-

sification of nanotechnology's dimensions, these can be di-

vided into three-dimensional (dendrimers, nanostructures, and

fullerenes), two-dimensional (nano-fibres, nanotubes, and

nanowires), and one-dimensional (nano thin films) categories

[22].

Role of Nanomedicine for Targeted Pharmaceutical Nanotechnology, xxxx, Vol. xx, No. x 3

2.1. Liposomes

Liposomes are typically spherical vesicles made of phos-

pholipid molecules and resemble cells [23]. For the admin-

istration of different nutrients, liposomes can be employed as

a medication delivery vehicle. These have a number of bene-

fits, including non-toxicity, prolonged-release pharmaceuti-

cals, non-immunogenicity, modifying drug distribution, hu-

manizing drug manifestation, giving up drug possession, etc.

[24]. To help with drug distribution, their applications have a

significant impact on biological fields. Drugs and substances

that are hydrophobic as well as hydrophilic can be captured

by liposomes [25]. Liposomes reduce the toxicity and dosage

due to the drug's long-lasting levels in the body. Liposomes

can be utilized to deliver chemicals such as insecticides, en-

zymes, and textile dyes. Because of their adaptable physical,

chemical, and biophysical features, these offer a careful deliv-

ery system. According to dosages and inflammatory reactions,

cationic liposomes, among other forms of liposomes, may be

cytotoxic. Neutral lipids [26] and pH-sensitive liposomes [27]

are the two key solutions to the issues discussed above.

2.2. Polymer Micelles Nanoparticles

Polymer micellar nanoparticles, which are both biode-

gradable and non-biodegradable, can significantly aid in the

distribution of drugs [28, 29]. The main building blocks of

synthetic polymer materials are polymers like poly (lactic-co-

glycolic acid) (PLGA), polyvinyl alcohol (PVA), polycapro-

lactone (PCL), and others that display biocompatibility, cell

non-toxicity, and stability with many or most drugs [30, 31].

Polysaccharides, sometimes known as peptides [32], and in-

clusion complexes are examples of natural polymers. These

micelles are typically produced through the self-assembly of

block amphiphilic copolymers, which are successfully em-

ployed to capture medications that cannot be dissolved [33].

Polymer nanoparticles can be used well in gastrointestinal en-

vironments and are structurally stable with favorable homo-

geneity to particle dimension and the recommended liberation

of medicines [34]. These polymeric micellar particles' enor-

mous surface area is encouraging for the uptake of medica-

tions and their sophisticated accessibility. Unfortunately, a

number of polymer nanoparticles have inherent drawbacks,

but structural modifications can address these issues [35, 36].

2.3. Dendritic Macromolecules

Dendrimers are artificial, highly branching, spherical,

mono-disperse, nanometer-sized macromolecules created us-

ing iterative synthetic processes. Numerous research teams

have contributed both synthetic methodology and particular

applications for this subject since the groundbreaking work on

dendrimer synthesis by Newkome et al. [37] in the early

1980s. The polyamidoamine (PAMAM) dendrimer family

may be the group of dendrimers that has received the greatest

attention for drug delivery. An amine functional core unit un-

dergoes a Michael addition reaction with methyl acrylate to

begin the divergent synthesis of PAMAM dendrimers. Due to

the development of two new branches per amine group as a

result, ester-terminated dendrimers, also known as “half-gen-

eration” dendrimers. The effectiveness and cost of manufac-

turing these macromolecules are constantly being improved.

In biological systems, dendritic macromolecules perform a

critical role. These macromolecules often have artificial

prongs and come in a variety of forms. The spherically shaped

macromolecules that are permitted in a dispersed environment

are worn as nano-carriers for the management and eradication

of impenetrable besieged medications. The peculiar pronged

molecules have a high degree of symmetry, and it is possible

to determine their molecular weight [38]. Dendritic macro-

molecules have a variety of biological features that make them

useful in the pharmaceutical and medical industries, but the

continued existence of façade accusations also restricts the use

of medical technology.

2.4. Metal Nanomaterials

Metal nanomaterials, which are composed of silver and

gold, are employed. These materials can take the form of nan-

owire, nano-capsules, nanoparticles, nanorods, or nano-cu-

boids [39-44]. In the photothermal treatment of malignancies

and rheumatoid arthritis, gold metal nanoparticles are utilized.

The main applications for silver nanoparticles are as antibac-

terial, anti-infection, and anti-tumor agents [45]. Some thera-

peutic medications are made from hollow gold or silver

nanostructures [46], or these materials can be chemically

linked to the surfaces of nanoparticles to deliver drugs to spe-

cific areas. However, the removal of gold nanomaterials from

the body of human beings is very deliberate, and the toxicity

confines the metal nanomaterials in treating persistent dis-

eases.

2.5. Inorganic Non-metallic Nanomaterials

The most common types of nanomaterials are silicon, gra-

phene, quantum dots, and Fe2O3 (iron oxide) [47, 48]. Due to

their unique shining characteristics, quantum dots (QDs) are

focused on fluorescence imaging, while nanoparticles made

of iron oxide are studied as MRI disparity agents [49-51]. Due

to their enormous surface area and porous nature, silicon na-

noparticles have been extensively exploited in the treatment

of diseases [52]. The incorporation of various functional

groups in inorganic nanoparticles has improved the transport

efficiency of pharmaceuticals. Additionally, it enhances mam-

mal cell genes. Although their biosafety would pose a signifi-

cant barrier to their use in health centers [53]. Fig. 1 displays

the typical varieties of nanodrug carriers.

2.6. Composite Nanomaterials

Due of their various characteristics, composite nano-

materials are employed as polymer or lipid nanoparticles to

create multifunctional NDDSs that contain both healing

agents and disparity agents. In vivo kinetic behavior, biocom-

patibility, and physicochemical properties of composite nano-

materials have been improved. By fusing different metals and

inorganic materials, NDDSs with distinctive structures and a

range of functions can be created [54, 55].

4 Pharmaceutical Nanotechnology, xxxx, Vol. x, No. x Hooda et al.

3. FEATURES OF NANOPARTICLES IN DRUG DE-

LIVERY

Due to the intricacy of delivery systems, some promising

compounds that have been recognized as potential therapeu-

tics for sensitive and persistent respiratory conditions have

been restricted. Protein, peptide, and mRNA release to the

lungs is a persistent issue in meticulous. Therefore, using nan-

otechnology to analyze potential targets is an impressive strat-

egy. Innovative methods to deliver medications to the location

of infected organs can be found in nanobiotechnology and na-

noscience. Due to anatomical, chemical, physiological, and

scientific hurdles to completion, certain tiny particle medica-

tions are subject to a number of restrictions that result in low

bioavailabilities and frequently the start of drug conflict [56,

57]. More than 90% of innovative medications fail, primarily

due to a lack of specificity for the target disease site, which

lowers both overall effectiveness and protection [58]. These

limitations have been overcome by nanotechnology, which

has improved and organized drug release while also delivering

improved and targeted drug delivery [59]. The development

of pharmacokinetics and an improvement in therapeutic bio-

distribution to target organs through the use of nanoscale drug

delivery devices ensures better efficacy while limiting medi-

cation toxicity. All the while, nanoparticles can improve the

distribution of medications across genetic barriers, control the

rate of medication release, and aid in the release of several

medications through various chemical and formulation tech-

niques. In order to incorporate equipment for investigative

and predictive monitoring during imaging while functionali-

zation with target moieties, nanoparticles can be eagerly mod-

ified with improved physical properties [60].

Nanocarriers include things like liposomes [61], inorganic

nanoparticles [62], and synthetic polymers [63]. Because it is

possible to precisely control their size, surface, and form,

nanocarriers are significant. Due of the large variety of pio-

neer materials, polymer design strategies, and multiple pre-

and post-modification interactions, these polymeric materials

may be important. In this regard, adaptable pathways and syn-

thetic approaches can be used to modify the stimuli-respon-

sive behaviors of drug delivery nanoparticles, enabling re-

sponse to environmental changes like pH, temperature

changes within infection states, or to externally applied stim-

uli like light and ultrasound [64]. Since oncology-focused pol-

ymeric therapeutics have dominated research in nanomedicine

for a long time, it is now conceivable to develop custom na-

noparticle formulations for other disease categories. Contra-

rily, there are very few examples of nanoparticle formulations

in the medical setting, despite the substantial research in the

field of nanomedicine and its huge effort to address the limi-

tations of the already practiced medical therapies [65].

A revolution in drug delivery techniques that distribute the

drug in the body in a prescribed manner from the point of

management to the therapeutic target has occurred as a result

of these systems being oppressed for medicinal purposes.

There are several academic fields that fall under the umbrella

of nanomedicine, including but not limited to those in the

fields of physics, chemistry, materials science, biology, and

biomedical sciences. Professionals who can communicate in

the engineering and biological languages are increasingly

needed in the industrial sector. Therefore, cross-training re-

straint creates new marketable scientists who can contribute

significantly to the nanomedicine sector Table 1.

Fig. (1). Common types of nano-drug carriers. (A higher resolution/colour version of this figure is available in the electronic copy of the article).

Role of Nanomedicine for Targeted Pharmaceutical Nanotechnology, xxxx, Vol. xx, No. x 5

Table 1. Role of nanoparticles for drug delivery.

Nano Carriers

Cancer Drug

Mechanism

Refs

SLN (solid lipid na-

noparticle)

Erlotinib HCl(metastatic

non-small cell lung cancer)

Poor oral bioavailability exists for erlotinib HCl. The presence of food demonstrates the

variety in the pharmacokinetics of erlotinib, especially absorption. Erlotinib HCl solid lipid

nanoparticles will be made in the current study, and their effects on bioavailability and

food-dependent absorption variability will be evaluated.

Liposome

pegylated liposomal doxo-

rubicin (Doxil)

We highlight recent advances in our understanding of the mechanisms underpinning the in

vivo interactions of liposomes with the tumor immune environment, as well as knowledge

gaps that need to be filled before cancer nanomedicines can fully realize their clinical po-

tential.

Polymeric Nanoparti-

cles (PEG-PLGA)

doxorubicin/gemicitabine

The polymeric drug carrier exhibits selective accumulation as well as an extended circula-

tion duration. The combination of radio- and chemo-therapy improves therapeutic efficacy

against cancer cells. They have also created polymer nanoparticels encapsulating taxanes

in order to improve chemotherapy efficacy while inhibiting adverse reactions.

Gold NPs

Doxorubicin (DOX),

In pancreatic cancer cells (PANC-1 and MIA PaCa-2), AuGO@ZC-DOX successfully

demonstrated improved cellular uptake, cytotoxicity, and anti-migration properties. Addi-

tionally, in a PANC-1 xenograft mouse model, the in vivo biodistribution and anti-tumor

effects of the NVs' chemo-phototherapeutic properties were promising.

Silver NPs

methotrexate drug

Anticancer activity testing in colon and lung cancer cells indicated the efficacy of drug-

conjugated AgNPs: conjugation improves the therapeutic impact of MTX while decreasing

the effective dosages of MTX necessary to achieve this effect.

Copper NPs

Copper-precursor

In vitro and in vivo anticancer therapeutic applications of cu and cu-derived NPs include

administration of medications, cancer imaging, image-guided therapy, PTT, and & devel-

oping techniques for selective targeting and minimizing potential toxins

Carbon nanotubes

(CNTs)

CNTs precursor

CNTs have the ability to deliver medications to specific cells and tissues.

3.1. Clinical Potentials in Drug Delivery System

Dynamic drugs intended to accumulate in infected region

specifically for an extended phase among elevated controlla-

bility in order to increase remedial possessions and decrease

associated elevation possessions. The technologies, formula-

tions, methods, and delivery systems for therapies are referred

to as drug delivery in order to convey them in the body in a

manner that achieves their desired effects as efficiently and

securely as possible [73]. Nanocarriers are generally referred

to as liposomes, polymers, and inorganic nanoparticles. With

the use of these systems, it will be possible to build clear-cut

traits like dosage and distribution, which will allow for con-

trolled release of the medicine and adequate distribution of

healing to the intended target while reducing adverse effects

[74, 75]. When compared to well-developed prescribed drug

administration systems, predictable drug delivery systems fre-

quently exhibit side effects that are mostly attributable to their

imprecise distribution and uncontrollable drug liberate dis-

tinctiveness [76, 77].

NDDSs are used to achieve the liberation of the loads at

target locations in a spatially constrained manner. The use of

sophisticated controlled NDDSs can successfully lower the

dosage rate of recurrence, while longer-term drug mainte-

nance in the organs/tissues is more difficult [78]. The use of

advanced systems, which selectively and specifically unite to

the infection object with regulated release activities, offers

vast insights and intriguing qualities for reducing medication

concentration instability, toxicity, and therapeutic effective-

ness. Assorted nano-materials offer the sophisticated DDSs

fresh business and creative opportunities due to their unique

small-scale qualities and intricate functions [79-81]. Even

though various innovative techniques for nanoparticles that

are worn as smart medication carriers have been urbanized

and summarized in reviews and investigations, only a small

number of these have finally been transformed into clinics for

practical applications [82-84]. As indicated in [85], there are

many essential mechanisms that need to be taken into account

to ensure medical efficacy for future commercialization.

3.2. ROLE OF NANO MEDICINE IN IMPROVING NA-

TURE

Since the beginning of time, the bioproducts made from

plants and animals have demonstrated a significant role in the

prevention and treatment of numerous human diseases. They

give the current medications substantial resources. The de-

mand for these organic goods resulting from plant monarchy

is constantly rising on the global market. Herbal goods and

extracts that are found in food, vitamins, and pharmaceuticals

make up the majority of the main products. Due to their enor-

mous structural diversity, natural goods undoubtedly repre-

sent a significant source of pharmaceuticals. To control the

liberating actions, polymers, lipids, and inorganic compounds

have been developed and used as drug carriers [86-91].

According to epidemiological studies [93] domestic live-

stock, including cattle, sheep, and pigs, are a major source of

these foodborne parasites. In fact, animal-derived goods like

milk and meat from diseased animals are sources of contami-

nation for both humans and other animals [94] as shown in

6 Pharmaceutical Nanotechnology, xxxx, Vol. x, No. x Hooda et al.

Fig. (2). Livestock play a major role in the transmission of FBDs caused by parasites, Reproduced with permission from [92]. (A higher

resolution/colour version of this figure is available in the electronic copy of the article).

Fig. 2. Bioavailability is "the rate and extent to which the dy-

namic component or active moiety is absorbed from a drug

creation and becomes available at the place of accomplish-

ment." Given that the drug is administered via intravenous ad-

ministration and enters the systemic circulation right away,

the dose of the medication is presumed to be 100% bioavaila-

ble. Other administration methods, such as intramuscular,

oral, and subcutaneous, typically have a bioavailability of less

than 100% [95]. Good solubility, a high rate of dissolution,

permeability, and susceptibility to various efflux mechanisms

are characteristics of oral administration that assist regulate

the rate and amount of drug absorption. Drugs are categorized

using BCS based on their solubility and permeability, which

control the rate and degree of their buried bioavailability.

Thus, BCS is an essential tool in drug.

3.3. Design Rationale of Smart Drug Delivery Nano plat-

forms

Smart nanoparticles are those that, in response to stimula-

tion, can release more drug molecules into the surrounding

area. The stimuli are made up of elements that are physical,

chemical, and biological (such as enzymes, antibodies, and

tiny molecules) as well as physical, chemical, and biological

(such as temperature, light, magnetic field, and electricity).

Nanomedicine has become a crucial tool for producing bio-

materials for pharmaceuticals, treatments, diagnosis, and in-

novative medical imaging [96]. For the delivery of drugs, a

variety of nanomaterials including lipids, polymers, lipo-

somes, surfactants, and proteins have been employed in nano-

medicines. Due to the significant interactions between the tis-

sues and these nanomaterials, they have been exploited in me-

dicinal applications [97]. Since several drug-based nanoparti-

cles have been produced, clinical studies are now being con-

ducted on a number of them for a range of infectious disor-

ders, including cancer, neurological diseases, inflammatory

diseases, and cardiovascular diseases. Only a small portion of

these goods, however, have human use approval [98]. The

main use of soft nanoparticles in drug loading is to improve

the biopharmaceutical, pharmacokinetic, and pharmacody-

namic aspects of the process. In addition, targeted drug distri-

bution (either passively or actively) and controlled drug re-

lease rates are made possible by nanoparticles, which can af-

fect the efficacy and safety of the therapy. The application of

these particles in nanomedicine has been prompted by their

antibacterial, antifungal, antiparasitic, and antiviral character-

istics, in addition to their soft and metal counterparts [99].

3.4. Nano medicine for Targeted Drug Delivery

The creation of nanoparticles has grown in importance as

a research topic because these structures allow for the con-

trolled release of cytotoxic medicines into the diseased re-

gions. The regulated release of cytotoxic medicines into the

diseased regions directly has become a crucial area of research

thanks to the creation of nanoparticles. Additionally, it is now

possible to send medications to areas affected by neoplastic

disease or inflammation. Nanomaterials must be used in vivo,

Role of Nanomedicine for Targeted Pharmaceutical Nanotechnology, xxxx, Vol. xx, No. x 7

which necessitates a detailed understanding of the basic mech-

anisms behind their actions in biological systems. To assure

the effectiveness of under-attack nanomedicine, some ele-

ments like inoculation sites or extravascular pathways must be

examined. The allocation, removal, and metabolism of nano-

materials in vivo are the most crucial aspects of intravenous

injection, but extravascular inoculation also includes other el-

ements like cellular absorption (endocytosis; phagocytosis,

and pinocytosis; receptor-meditated endocytosis). By envel-

oping foreign substances with their cell membrane, endocyto-

sis is the process by which cells take in particles, chemicals,

and liquids from the outside world. All of the body's cells use

this mechanism to produce the necessary substances. The cel-

lular function of large molecules that are unable to pass the

hydrophobic plasma membrane can also be used it. By adding

stealth coatings to the surfaces of nanoparticles and changing

the surface chemistry, it is possible to prevent the endocytosis-

induced inclusion of nanomedicine at undesirable places. Na-

noparticles that have not been changed are quickly absorbed

in the circulation and left unattended by macrophages [100].

The stealth coating can increase anticancer effectiveness and

lengthen the half-life of medications in circulation by concen-

trating high therapeutic concentrations in diseased areas. Bio-

compatibility, which can be improved by changing the termi-

nal groups on the surface of nanomaterials as well as their

component elements, is the most important defining feature of

nanomedicines, particularly in terms of surface chemistry.

The mononuclear phagocyte system (MPS) is less receptive to

nanoparticles stabilized in the reticuloendothelial system

(RES) by chemical alteration or by the addition of an outer

shell [101].

Any multifunctional nanomedicine carrier must have

strength and long-lasting pharmacological effects. One of the

main reasons for the development of long-circulating effects

is the requirement of the pharmaceutical agent's restorative

point in the circulation for a prolonged period of time. Af-

fected areas will gradually develop large macromolecular ag-

gregates or drug-containing microparticles, which will in-

crease retention and permeability. Additionally, the extended

circulation half-life improves the targeting properties for

some ligand-modified drugs and drug carriers, giving them

more opportunity to interact with sick areas because there are

more pharmacological passages within the target period [102].

4. CHALLENGES TO BE OVERCOME

Nanomedicines shows slow uptake in medical due to five

major challenges which are discussed below [103]:

(1) The majority of nanomedicines rely on EPR-mediated

subservient targets to improve delivery to the disease position,

but it is becoming more and more obvious that these vascular

fenestrations are extremely variable even within the same tu-

mor mass [104] and are not significant for slowly growing tu-

morous cells [105].

(2) In certain instances, the therapeutic impact is intrinsi-

cally overestimated in preclinical testing of nanoparticle for-

mulations on mammal models and is not sufficiently dele-

gated in human subjects [106].

(3) In order to achieve successful transformation, nano-

materials formulations and applications should be simple,

generally applicable, and reproducible in design [107].

(4) It is crucial to reduce artificial complexity, harmful pu-

rifying steps, and the amount of divergent mechanisms in or-

der to maintain dependability, medical application, and robust

scalability when creating customized polymer nanoparticles,

even though this facilitates expansion and cost-efficiency for

the pharma-production.

(5) By understanding how natal connections impudence

the accretion or approval of nanoparticles after delivery is

very imperative for conversion and during proscribed biodeg-

radation of nanoparticle, it is possible to achieve the long-term

protection of nanomedicines [108].

The development of fresh strategies to overcome these ob-

stacles and conceptual shortcomings can hopefully flourish

for the advantages of therapeutic nanomedicines. Nanoparti-

cles hold great potential and can be crucial in the treatment of

cancer, despite the fact that gathering evidence with the aim

of the EPR effect is not the miraculous solution we may hope

for [109, 110]. Recent nanomedicines have been shown to be

more effective than free pharmaceuticals when their solubil-

ity, bioavailability, and toxicity have been combined [111,

112]. The main focus of the work is on nanoparticle intends

factors that can achieve possible material growth. The ability

to overcome the major drawbacks of extra traditional relief

vectors like liposomes and polymer pharmaceuticals was pro-

vided by polymeric-based nanomedicines. The physical and

chemical properties of the nanomedicines can influence the

tum-or accretion and it is well recognized that magnitude,

character, and surface chemistry administrate nanoparticle up-

take into the tumor places as shown in Fig. 3 [113-115].

According to research, the number of drug delivery parti-

cles will determine the in vivo outcome and hinder approval

processes. Screening should be done at a smaller perimeter of

5 nm to minimize renal filtration and at a broader perimeter of

200 nm to prevent excessive liver and spleen accretion [116-

118]. While condensed protein accessory is present in parti-

cles bigger than 100 nm [119], which leads in extended blood

half-lives in vivo [120,121], condensed protein accessory is

absent in particles smaller than 100 nm [119]. Due to the elec-

trostatic interaction between particles and cell surfaces, minor

detrimental external potential can reduce nonspecific absorp-

tion into the liver and spleen [122]. It has been shown that the

particle's hydrophobic surfaces encourage interactions with

blood proteins, which slow down approval. Therefore, the

problem might be remedied by covering the hydrophilic sur-

face with layers of poly (ethylene glycol) (PEG) [123, 124].

The fact that a comparable nature can impair cellular absorp-

tion should be emphasized [125]. However, due to steric re-

pulsion forces, PEG high density chains can prevent opsonin

proteins from being absorbed, which leads to a lesser uptake

by macrophages and, as a result, a prolonged blood circulation

period. Since the hydrophobic surfaces of the particles, on the

other hand, increase absorption due to their attraction for lipid

bilayers, a balance between the two elements must be estab-

8 Pharmaceutical Nanotechnology, xxxx, Vol. x, No. x Hooda et al.

lished [126]. The efficiency of nanoparticles for extravasa-

tion, transit into the cancer interstitial space, and internaliza-

tion by the target cancer cells is determined by their physico-

chemical qualities [127-129]. The former is primarily medi-

ated by crucial elements of the delivery strategy, whilst the

latter can be significantly improved by encapsulating power-

ful target ligands [130].

5. ROLE OF NANOMEDICINES FOR CANCER TAR-

GETING

By a number of processes, nanoparticles have improved

the delivery of cancer drugs. By passively targeting a noncar-

rier in the past, the nonspecific accumulation of drug transport

into sick tissue has increased and developed. Maeda proposed

the enhanced permeation and retention (EPR) effect on the ef-

fectiveness of in vivo anticancer protein-polymer conjugates

in 1986 [61]. It accumulates more in tumor tissues than free

protein does. The identical behavior of other proteins like al-

bumin and transferrin led to the proposal of the EPR effect

[131]. The EPR effect is caused by the rapid proliferation of

the tumor cells, which reduces nutrient levels and causes an-

giogenesis, the unregulated growth of new, damaged blood

vessels. Depending on the type and location of the tumor, the

newest or new arteries may have permeable pores of 1 m in

size, which may encourage extravasations of circulating na-

noparticles into the tumor's surrounds and increase penetra-

tion. Fig. 4 illustrates that macromolecules larger than 4 nm

are more likely to be retained because the lymphatic drainage

system, which carries solutes into interstitial fluid and back

into circulation in healthy tissues, is disrupted.

Fig. (3). The biodistribution among the many organs, such as the lungs, liver, spleen, and kidneys, is determined by nanoparticle size, shape,

and surface charge. (A higher resolution/colour version of this figure is available in the electronic copy of the article).

Fig. 4. Nano careers fight against cancer. (A higher resolution/colour version of this figure is available in the electronic copy of the article).

The nanomedicine industry has experienced tremendous

growth as a result of Ehrlich's 1906 prediction that site-spe-

cific medication delivery with minimal off-target damage will

be the "magic bullet" of drug administration [132, 133]. Dox-

orubicin and amphotericin B liposome formulations are the

first nanomedicines available at the clinic. Oncaspar

Role of Nanomedicine for Targeted Pharmaceutical Nanotechnology, xxxx, Vol. xx, No. x 9

(PEGylated L-asparaginase), Abraxane (albumin-bound

paclitaxel), and Genexol-PM (mPEG-PDLLA micellar

paclitaxel), among other anticancer medications, were among

the 51 nanomedicines that were approved by FDA for use

since 2016 [134, 135]. On the other hand, as of yet, marketa-

ble goods have not taken into account this study's concern and

clear excess of potential preclinical repercussions. Addition-

ally, many of them have more than 70 medications undergoing

clinical studies, which shows that more and more formula-

tions are being released onto the market.

6. ACTIVE TARGETING OF NANOPARTICLES

The EPR effect allows circulating nanoparticles to first in-

filtrate the tumor bulk, where they are then recognized by cel-

lular receptors and taken up by cells [136]. It appears that

adopting an active targeting mechanism can address many of

the issues with passive targeting systems. Due to the discovery

of disease-specific biomarkers, nanomedicine has gone in this

direction [137]. In order to specifically engage with antigens

or receptors that are either uniquely articulated or overex-

pressed on tumor cells in comparison to normal tissues, active

targeting often entails using one or more targeting moieties

conjugated to nanoparticle surfaces. Assuming internalizing

receptors are inhibited, this technique has the added benefit of

stimulating the transport of nanoparticles into cells through a

specific pathway before they reach the tumor extracellular

space [138]. Ligands may also be used to target intravascular

tumor cells or tumor blood stream endothelial cells in order to

promote the accretion of nanoparticles inside the site of the

disease [139-141]. It is suggested that combining an active tar-

geting mechanism with improved nanoparticle design could

result in a more effective drug carrier [142]. In the past ten

years, a large number of publications have shown the devel-

opment of techniques for functionalizing nanoparticles with

particular ligands and evaluating their efficacy in preclinical

settings. A synthetic targeting moiety and antibody binding to

a specific cell surface protein are examples of active targeting

techniques [143]. The specific uniqueness of the target recep-

tor, as well as the receptor expression, whether internalization

is possible or required, the design and biodistribution of the

nanoparticle itself, and the characteristics of the target tumors

all have an impact on the ligand used to target the carrier

[144].

7. IMAGING

Imaging plays a significant role in the preclinical evalu-

ation of drug delivery systems based on nanomedicine, of-

fering vital insights into their mode of operation and thera-

peutic impact. Less focus has been paid to its role in helping

the clinical development of nanomedicine products. The en-

hanced permeability and retention/maintenance (EPR) effect

occurs in patients despite comparably high levels of inter and

intra individual variability, according to these findings,

which are important since they demonstrate credible nano-

medicine uptake. It is becoming more and more obvious that

imaging is essential for addressing this enormous heteroge-

neity. This theory has recently been supported by two sepa-

rate studies in patients that demonstrated a strong correlation

between tumor absorption of nanomedicine and anticancer

efficacy. The image-guided medication delivery can help to

complement improved and customized nanomedicine treat-

ments [105].

Imaging may serve an additional purpose in the therapeu-

tic setting because of the variability of people and diseases. It

is widely known that human/disease heterogeneity affects the

effectiveness of all treatments, but it is particularly detri-

mental to the clinical success and translation of therapeutic

nanomedicines [145, 146]. In contrast to animal models of

disease, where the efficacy of drug delivery systems is fre-

quently assessed using the same genetic strains of mice and

disease cell lines, heterogeneity exists in humans between pa-

tients with different diseases, those with the same disease, and

even within different lesions of the same patient. Due to this

diversity, nanomedicines have primarily been approved based

on their improved safety profile compared to traditional phar-

maceuticals rather than their therapeutic efficacy [147]. Imag-

ing technologies that allow us to predict the effectiveness of

medication delivery systems as well as other therapies at the

patient-to-patient level may therefore be highly important in

the future [145]. The purpose of this study is to examine the

development of imaging drug delivery in people and the pro-

spects for the future. We first wish to give a historical over-

view of how different clinical imaging modalities have con-

tributed to the conversion of drug delivery systems into com-

mercially viable devices by presenting proof of concept data.

We also aim to show how imaging can be used to predict drug

distribution and treatment results, as well as how current re-

search is shedding new light on the problem of inter- and in-

tra-patient heterogeneity. The research findings from all of

these studies that, in our judgment, warranted greater study

were highlighted whenever it was possible. to find clinical

studies for image-guided surgery. Most studies used imaging

liposomes radiolabeled with Tc-99m or In-111 to measure

drug distribution to tumor sites. Early clinical trials were car-

ried out to ascertain the safety of the liposomes as well as their

usage as imaging agents for tumor detection and staging after

preclinical investigations demonstrated liposome accumula-

tion in malignancies [148-150]. For instance, Tc-99m labeled

liposomes were given to seven cancer patients by Lopez-Ber-

estein et al. [151]. Early-generation liposomes were mainly

viewed as a method to lessen the toxicity of their payload or

to target macrophages because it was unknown if they prefer-

entially accumulated at tumor locations. The study found that

liposomes were found in tissues rich in macrophages, such as

the liver, spleen, and lungs, but no accumulation was seen in

tumor areas. It's unlikely that this could have been observed

given that four of the seven patients had leukemia of different

sorts and that one of the patients had a solid tumor while the

other was in complete remission. Within Fig. 5, this research

is significant because it shows how radiolabeled liposomes

may be administered to humans safely and very easily. Turner

et al. conducted the first clinical research employing In-111-

labeled liposomes, which verified the technique's safety [152,

153].

10 Pharmaceutical Nanotechnology, xxxx, Vol. x, No. x Hooda et al.

8. USE OF NANOPARTICLES IN IMAGING

In addition to being utilized for imaging diagnoses at the

anatomical level, nanoparticles may also be employed for

molecular imaging, which can aid in further detailed analy-

sis with skyrocketing valuable images at the cellular level.

In fact, unique agents have been given more weight in the

diagnosis of tumor and atherosclerosis. Various nanoparti-

cles can be employed with MRI, fluorescence, ultrasound,

computed tomography, and nuclear imaging [154, 155].

Gadolinium complexes have been included into the suspen-

sion of the nanoparticles, increasing the indications in com-

parison to conventional disparity agents [156]. Animal rep-

resentation urbanized in rabbits has shown that ultra-small

supra magnetic Fe2O3 particles have improved the MRI sig-

nal. Stem cell imaging is the emerging area in the MRI Table

2. Stem cell imaging works is, the treatment of stem cells

with supra magnetic nanoparticles, further these can be in-

oculated to a precise location in the human body. The cells

have the ability to consume the nanoparticles resulting in the

accretion of nanoparticles intracellular which can apply a

confined consequence for the recognition of cell [157, 158].

9. USE OF NANOTECHNOLOGY IN NEURODEGEN-

ERATIVE DISORDERS

Nanotechnology may have significant applications in the

treatment of neurodegenerative diseases [165, 166]. For use in

treating the central nervous system, researchers are looking

into nanocarriers such as dendrimers, liposomes, nanoemul-

sions, nanosuspensions, polymeric nanoparticles, nanogels,

and solid lipid nanoparticles. Different blood-brain barrier

systems are employed for the delivery of medications [167-

169]. The CNS has been successfully treated in preclinical tri-

als for diseases such as brain tumors, Alzheimer's disease,

acute ischemic stroke, and HIV encephalopathy. Nanomedi-

cines can be strengthened by enhancing blood-brain barrier

permeability and reducing neurotoxicity [42, 165, 169-172].

The numerous nanocarriers for neurological disorders target-

ing Figure 6 are discussed in Table 3.

Fig. (5). Application of nanoparticles in Bioimaging. (A higher resolution/colour version of this figure is available in the electronic copy of

the article).

Table 2: Role of Nanoparticles for Bioimaging

Nanocarriers

Bio-imaging Technique

Application

Reference

Quantum-dots

fluorescent nanoparticles for bioimaging

Tumor cells that have been specifically imaged

159

AuNPs

Infrared (IR) imaging

Detection of lymph nodes

160

Carbon NPs

Fluorescein isothiocyanate (FITC)

Monitoring the administration of medicinal drugs

161

Liposomal-iodine

CT scans

Identifying the vascular anatomy of a tumor

162

AuNP

Computed tomography (CT) scans

Imaging brain tumors and enhancing radiation

163

Cu-TNP

Positron emission tomography (PET)

Imaging brain tumors and enhancing radiation

164

Role of Nanomedicine for Targeted Pharmaceutical Nanotechnology, xxxx, Vol. xx, No. x 11

Table 3. Role of Nanotechnology for Neurological.

Nano Carrier

Neurological Disordered

Mechanism

Refs.

SLN (solid lipid

nanoparticles)

Ischemic Stroke, Epilepsy,

Parkinson’s disease (PD),

And Alzheimer’s disease

(AD)

By using natural blood-brain barrier transport mechanisms, SLNs were created to ad-

dress those issues. For instance, apolipoproteins from the systemic circulation are bound

by drug-loaded SLN, which then releases medicines at the target site after being taken up

by endothelial cells by endocytosis mediated by low-density lipoprotein (LDL)-recep-

tors.

173

Liposome Curcu-

min

(LipocurcTM)

The pharmacokinetics data from LipocurcTM's Phase 1 trial show a highly favourable

safety and tolerability profile for the prospective PD therapeutic lead. We conclude that

both translational and clinical investigations of curcumin provide more transformational

nanotechnology-driven epigenetic-based Parkinson's disease treatments platform for

clinical usage.

174

Polymeric Nano-

particles (PEG-

PLGA)

The lactoferrin (Lf) conjugated PEG-PLGA nanoparticle (Lf-NP) was developed in this

publication, and its in vitro and in vivo transport characteristics were examined using the

fluorescent probe coumarin-6.

The system's tolerable toxicity was verified by the cell viability test and CD68 immuno-

histochemistry. All of these findings indicated that Lf-NP was a feasible brain medica-

tion delivery method with low toxicity.

175

Gold NPs

AD & PD

Inhibited Aß peptide aggregation and Aß aggregate degradation; inhibited acetylcholin-

esterase and butyrylcholinesterase; anti-inflammation

176

Silver NPs

Researchers are very interested in the amyloid-peptide oligomer (AO) due to its clinical

therapeutic intervention targets and the significance of precise biological macromolecule

markers for early Alzheimer's disease diagnosis.

177

Copper NPs

AD & PD

Copper is a biogenic metal with numerous functions in basic biological processes. About

copper toxicity, neurodegenerative disorders are considered to be associated to copper

toxicity. Copper nanoparticles are another issue due to their high toxicity and understood

mechanism of action in the body. Because of the copper significance and seriousness of

the pathogenic processes that copper and copper nanoparticles can begin, the impact of

copper and copper nanoparticles on organisms should be researched further.

178

Carbon nano-

tubes (CNTs)

We reviewed the most recent advances in the in vitro and in vivo scientific and therapeu-

tic applications of CNTs for the treatment of neurological disorders as naturally occur-

ring therapeutic drugs. The processes of CNT-mediated bio-medical benefits and poten-

tial CNT toxicity have also received a lot of attention, and it is expected that they may

soon have more neurological uses in the treatment of disease.

179

Fig. (6). Role of various nanocarri6rs for neurological disease targeting. (A higher resolution/colour version of this figure is available in the

electronic copy of the article).

12 Pharmaceutical Nanotechnology, xxxx, Vol. x, No. x Hooda et al.

10. DRAWBACKS AND THEIR SOLUTIONS TO

NANO-MEDICINE APPLICATIONS AS A DRUG

DELIVERY SYSTEM

The dangers posed by employing nanoparticles for medi-

cine administration go beyond those that are typically im-

posed by chemicals in traditional delivery matrices. The un-

derstanding of particle toxicity for nanoparticles as deter-

mined by inhalation toxicity illustrates how to look into the

potential risks of nanoparticles. The toxicology of particulate

matter is different from that of substances because the chemi-

cal(s) that make up the particulate matter may or may not be

soluble in biological matrices, which has a significant impact

on the possible exposure of various internal organs. Depend-

ing on the chemical, there may be a very high local exposure

in the lungs and a very low or negligible exposure for other

organ systems following inhalation [179]. The potential tox-

icity of the inhaled particles, however, may also be influenced

by the species that are absorbed. The situation is different for

nanoparticles because of their small size, which makes it pos-

sible for them to pass through a variety of internal biological

barriers. In order to detect a variety of potential risks, specific

routine assays must be carried out for medical applications.

However, it is to be expected that not all risks associated with

the usage of nanoparticles are now understood. The evidence

supporting the toxicity of NPs used in healthcare goods was

examined by Costigan [180] in a recent publication. Her find-

ings once more emphasized how little information exists on

the toxicity of the NPs being used. However, conventional

hazard identification testing, which is now necessary to meet

with the rules for healthcare products, might identify the ma-

jority, if not all, causes of toxicity in NPs for healthcare prod-

ucts. However, it is possible that not all dangers will be found,

necessitating more targeted testing. Additionally, nanotech-

nology encourages the blending of technologies; for instance,

similar materials may be used in the automobile and health

sciences industries. Data interchange between sectors is ad-

vised to promote the manufacturing and marketing of safe na-

nomaterials. Pharmaceutical sciences have used nanoparticles

to lessen the toxicity and adverse effects of medications for

many years. It wasn't known until recently that the carrier sys-

tems themselves could present dangers to the patient. Beyond

the typical risks given by chemicals in delivery matrices, new

risks are added by the use of nanoparticles for medication ad-

ministration. However, there is currently no scientific para-

digm for the potential (adverse) reactivity of nanoparticles,

and we know very little about the fundamentals of how nano-

particles interact with living cells, organs, and animals [181].

CONCLUSIONS

The discovery of liposomes and nanoparticles with na-

nometer-sized carriers offers significant possibilities for anal-

ysis and cutting-edge delivery techniques for resistance in-

flection in respiratory illnesses. Nanoparticles can also be em-

ployed successfully to spread immunologically dynamic ma-

chinery for perceptive or persistent lung diseases. Even

though it still needs to be accepted on a medical level, the abil-

ity to target particular cells in tissue without damaging nearby

organs due to adverse drug processes offers an interesting pro-

spect for research. The use of nanomedicine may potentially

help to control illnesses like ventilator-associated pneumonia

by employing endotracheal tubes coated with nanoparticles

that have a variety of antibacterial properties. One of the med-

icine categories that could be significantly impacted by the

use of nanotechnology in pharmaceutical administration is

lung illnesses. Nanomedicine has several advantages, includ-

ing enhanced bioavailability, restricted release, and tailored

distribution with low toxicity. However, as these haven't been

considered in medical contexts, it will be necessary to recog-

nize the value of protection, large-scale manufacturing, and

pricing. Translational research using various nanotechnology

platforms will need to show safety, value, and clear therapeu-

tic benefits over existing treatments for respiratory disorders

in order to prove cost-effectiveness in manufacturing. Exact de-

tached testing will be required to understand the harmful con-

sequences of nanoparticles when delivered to the lungs. It is es-

sential to continue translational studies employing nanomedi-

cine in order to expand novel, effective medicines. The spread

of FBDs brought on by parasites has been more of a concern

during the past ten years. Foodborne parasites do indeed carry

a heavy burden of disease in humans, according to a recent

FERG analysis. The appropriate strategies to accomplish this

goal are not well-defined, despite the fact that it is obvious that

the burden of disease caused by these specific parasites must be

reduced. The choice of the optimal management measure is ac-

tually very tough because each of these parasites, as well as the

FBD that it is connected with, has distinct demanding charac-

teristics. Since a variety of elements, including biological and

technological criteria, as well as available resources, must be

taken into account, it is necessary to discuss the applicability of

livestock vaccination as a measure to reduce foodborne para-

sitic infections for each FBD. Unquestionably, vaccination of

farm animals improves animal health and lowers financial

losses related to the livestock industries. Without a doubt, the

use of nanomedicine and nano-drug delivery systems is the cur-

rent and future trend that will dominate research and develop-

ment for decades to come. This is due to the fact that it employs

various kinds of nanoparticles to transport the exact dosage of

medication to the affected cells, such as cancerous or tumor

cells, without interfering with the regular cells' physiology.

Even while nanomedicine and nano-drug delivery technologies

are well understood, their actual influence on the healthcare

system, notably in the prevention and treatment of cancer, is

still fairly limited. This is because the industry has only recently

undergone two decades of serious study and is still mostly un-

discovered. There are still many significant, fundamental traits

that are unknown.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

JRA gratefully acknowledges the Department of Packag-

ing, Yonsei University, South Korea for their cooperation and

financial support.

Role of Nanomedicine for Targeted Pharmaceutical Nanotechnology, xxxx, Vol. xx, No. x 13

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or

otherwise.

ACKNOWLEDGEMENTS

NH and AA are thankful to the Dean and HOD, Depart-

ment of Physical Sciences, PDM University, Bahadurgarh for

all their cooperation and support in finalizing the paper. MSA

is thankful to SGT University for their cooperation and sup-

port.

REFERENCES

[1] Sadikot RT, Rubinstein I. Long-acting, multi-targeted nanomedicine:

addressing unmet medical need in acute lung injury. J Biomed Nan-

otechnol 2009; 5(6): 614-9.

http://dx.doi.org/10.1166/jbn.2009.1078 PMID: 20201223

[2] Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in tar-

geted drug delivery and imaging: a concise review. Nanomedicine

2005; 1(3): 193-212.

http://dx.doi.org/10.1016/j.nano.2005.06.004 PMID: 17292079

[3] Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomed-

icine landscape. Nat Biotechnol 2006; 24(10): 1211-7.

http://dx.doi.org/10.1038/nbt1006-1211 PMID: 17033654

[4] Singhal S, Gupta M, Alam MS, Javed MN, Ansari JR. Carbon Allo-

tropes-Based Nanodevices: Graphene in Biomedical Applications

InNanotechnology. CRC Press 2022; pp. 241-69.

http://dx.doi.org/10.1201/9781003220350-14

[5] Bhandari M, Raj S, Manchanda R, Alam MS. Review on natural bi-

oactive products as radioprotective therapeutics: Present and past

perspective. Curr Pharm Biotechnol 2022; 23(14): 1721-38.

http://dx.doi.org/10.2174/1389201023666220110104645

PMID: 35016594

[6] Kumar R, Dhamija G, Ansari JR, Javed MN, Alam MS. C-Dot nano-

particulated devices for biomedical applications. In: Nanotechnol-

ogy. CRC Press 2022; pp. 271-99.

[7] Bharti C, Alam MS, Javed MN, Khalid M, Saifullah FA, Manchanda

R. Silica based nanomaterial for drug delivery. Nanomaterials. Evo-

lution and Advance Towards Therapeutic Drug Delivery 2021; (Part

2): 57-89.

[8] Pandit J, Alam MS, Javed MN, Waziri A, Imam SS. Emerging roles

of carbon nanohorns as sustainable nanomaterials in sensor, catalyst,

and biomedical applications. In: Handbook of Green and Sustainable

Nanotechnology: Fundamentals, Developments and Applications.

Cham: Springer International Publishing 2023; pp. 1-27.

[9] Mall SK, Yadav T, Waziri A, Alam MS. Treatment opportunities

with Fernandoa adenophylla and recent novel approaches for natural

medicinal phytochemicals as a drug delivery system. Exploration of

Medicine 2022; 3(6): 516-39.

http://dx.doi.org/10.37349/emed.2022.00111

[10] Bhandari M, Kaur DP, Raj S, Yadav T, Abourehab MA, Alam MS.

Electrically conducting smart biodegradable polymers and their ap-

plications. In: Handbook of Biodegradable Materials. Cham:

Springer International Publishing 2023; pp. 391-413.

http://dx.doi.org/10.1007/978-3-031-09710-2_64

[11] Naseh MF, Ansari JR, Alam MS, Javed MN. Sustainable nanotorus

for biosensing and therapeutical applications. In: Handbook of Green

and Sustainable Nanotechnology: Fundamentals, Developments and

Applications. Cham: Springer International Publishing 2022; pp. 1-

21.

http://dx.doi.org/10.1007/978-3-030-69023-6_47-1

[12] Sunilbhai CA, Alam MS, Sadasivuni KK, Ansari JR. SPR assisted

diabetes detection. In: Advanced Bioscience and Biosystems for De-

tection and Management of Diabetes. Cham: Springer International

Publishing 2022; pp. 91-131.

http://dx.doi.org/10.1007/978-3-030-99728-1_6

[13] Singhal S, Gupta M, Alam MS, Javed MN, Ansari JR. Carbon allo-

tropes-based nanodevices: Graphene in biomedical applications. In:

Nanotechnology. CRC Press 2022; pp. 241-69.

http://dx.doi.org/10.1201/9781003220350-14

[14] Rampado R, Peer D. Design of experiments in the optimization of

nanoparticle-based drug delivery systems. J Control Release 2023;

358: 398-419.

http://dx.doi.org/10.1016/j.jconrel.2023.05.001 PMID: 37164240

[15] Ramazanli VN. Effect of ph and temperature on the synthesis of sil-

ver nano particles extracted from olive leaf.

https://www.ablesci.com/assist/detail?id=X1zbZA

[16] Nasibova A. Generation Of Nanoparticles In Biological Systems

And Their Application Prospects, Advances in Biology &. Earth Sci

8: 2023. n.d.

[17] Ahmadov IS, Bandaliyeva AA, Nasibova AN, Hasanova FV, Kha-

lilov RI. The synthesis of the silver nanodrugs in the medicinal plant

baikal skullcap (scutellaria baicalensis georgi) and their antioxidant,

antibacterial activity. In: Advances in Biology & Earth Sciences.

2020.

[18] Ouyang J, Zhang Z, Deng B, et al. Oral drug delivery platforms for

biomedical applications. Mater Today 2023; 62: 296-326.

http://dx.doi.org/10.1016/j.mattod.2023.01.002

[19] Cooke JP, Atkins J. Nanotherapeutic solutions for cardiovascular dis-

ease. Methodist DeBakey Cardiovasc J 2016; 12(3): 132-3.

http://dx.doi.org/10.14797/mdcj-12-3-132 PMID: 27826365

[20] Zhou X, Hao Y, Yuan L, et al. Nano-formulations for transdermal

drug delivery: A review. Chin Chem Lett 2018; 29(12): 1713-24.

http://dx.doi.org/10.1016/j.cclet.2018.10.037

[21] Matoba T, Koga J, Nakano K, Egashira K, Tsutsui H. Nanoparticle-

mediated drug delivery system for atherosclerotic cardiovascular dis-

ease. J Cardiol 2017; 70(3): 206-11.

http://dx.doi.org/10.1016/j.jjcc.2017.03.005 PMID: 28416142

[22] Versatile flexible azolate-based metal-organic frameworks pos-

sessing different bridging ligands. J Mater Res 2016; 4(2)

[23] Landesman-Milo D, Goldsmith M, Leviatan Ben-Arye S, et al. Hya-

luronan grafted lipid-based nanoparticles as RNAi carriers for cancer

cells. Cancer Lett 2013; 334(2): 221-7.

http://dx.doi.org/10.1016/j.canlet.2012.08.024 PMID: 22935680

[24] Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based

drug delivery systems in cancer therapy: what is available and what

is yet to come. Pharmacol Rev 2016; 68(3): 701-87.

http://dx.doi.org/10.1124/pr.115.012070 PMID: 27363439

[25] Chandrasekaran S, King M. Microenvironment of tumor-draining

lymph nodes: opportunities for liposome-based targeted therapy. Int

J Mol Sci 2014; 15(11): 20209-39.

http://dx.doi.org/10.3390/ijms151120209 PMID: 25380524

[26] Chapoy-Villanueva H, Martinez-Carlin I, Lopez-Berestein G,

Chavez-Reyes A. Therapeutic silencing of HPV 16 E7 by systemic

administration of siRNA-neutral DOPC nanoliposome in a murine

cervical cancer model with obesity. J BUON 2015; 20(6): 1471-9.

PMID: 26854443

[27] Fan Y, Chen C, Huang Y, Zhang F, Lin G. Study of the pH-sensitive

mechanism of tumor-targeting liposomes. Colloids Surf B Biointer-

faces 2017; 151: 19-25.

http://dx.doi.org/10.1016/j.colsurfb.2016.11.042 PMID: 27940165

[28] Shi C, He Y, Ding M, Wang Y, Zhong J. Nanoimaging of food pro-

teins by atomic force microscopy. Part I: Components, imaging

modes, observation ways, and research types. Trends Food Sci Tech-

nol 2019; 87: 3-13.

http://dx.doi.org/10.1016/j.tifs.2018.11.028

[29] Shi C, He Y, Ding M, Wang Y, Zhong J. Nanoimaging of food pro-

teins by atomic force microscopy. Part II: Application for food pro-

teins from different sources. Trends Food Sci Technol 2019; 87: 14-

25.

http://dx.doi.org/10.1016/j.tifs.2018.11.027

[30] Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V.

PLGA-based nanoparticles: An overview of biomedical applications.

J Control Release 2012; 161(2): 505-22.

http://dx.doi.org/10.1016/j.jconrel.2012.01.043 PMID: 22353619

[31] Wei D, Qiao R, Dao J, et al. Soybean lecithin‐mediated nanoporous

PLGA microspheres with highly entrapped and controlled released

BMP‐2 as a stem cell platform. Small 2018; 14(22): 1800063.

http://dx.doi.org/10.1002/smll.201800063 PMID: 29682876

14 Pharmaceutical Nanotechnology, xxxx, Vol. x, No. x Hooda et al.

[32] Zhao L, Ding J, Xiao C, et al. Glucose-sensitive polypeptide micelles

for self-regulated insulin release at physiological pH. J Mater Chem

2012; 22(24): 12319-28.

http://dx.doi.org/10.1039/c2jm31040f

[33] Afsharzadeh M, Hashemi M, Mokhtarzadeh A, Abnous K, Ramezani

M. Recent advances in co-delivery systems based on polymeric na-

noparticle for cancer treatment. Artif Cells Nanomed Biotechnol

2018; 46(6): 1095-110.

http://dx.doi.org/10.1080/21691401.2017.1376675

PMID: 28954547

[34] Wang W, Ding J, Xiao C, et al. Synthesis of amphiphilic alternating

polyesters with oligo(ethylene glycol) side chains and potential use

for sustained release drug delivery. Biomacromolecules 2011; 12(7):

2466-74.

http://dx.doi.org/10.1021/bm200668n PMID: 21649444

[35] Yang C, Gao S, Dagnæs-Hansen F, Jakobsen M, Kjems J. Impact of

PEG chain length on the physical properties and bioactivity of

PEGylated chitosan/siRNA nanoparticles in vitro and in vivo. ACS

Appl Mater Interfaces 2017; 9(14): 12203-16.

http://dx.doi.org/10.1021/acsami.6b16556 PMID: 28332829

[36] Sun P, Huang W, Kang L, et al. siRNA-loaded poly(histidine-argi-

nine)6-modified chitosan nanoparticle with enhanced cell-penetrat-

ing and endosomal escape capacities for suppressing breast tumor

metastasis. Int J Nanomedicine 2017; 12: 3221-34.

http://dx.doi.org/10.2147/IJN.S129436 PMID: 28458542

[37] Newkome GR, Yao Z, Baker GR, Gupta VK. Micelles. Part 1. Cas-

cade molecules: a new approach to micelles. A [27]-arborol. J Org

Chem 1985; 50(11): 2003-4.

http://dx.doi.org/10.1021/jo00211a052

[38] Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for

the delivery of small interfering RNA. Biomaterials 2012; 33(29):

7138-50.

http://dx.doi.org/10.1016/j.biomaterials.2012.06.068

PMID: 22796160

[39] Baeza A, Ruiz-Molina D, Vallet-Regí M. Recent advances in porous

nanoparticles for drug delivery in antitumoral applications: inorganic

nanoparticles and nanoscale metal-organic frameworks. Expert Opin

Drug Deliv 2017; 14(6): 783-96.

http://dx.doi.org/10.1080/17425247.2016.1229298

PMID: 27575454

[40] Alam MS, Garg A, Pottoo FH, et al. Gum ghatti mediated, one pot

green synthesis of optimized gold nanoparticles: Investigation of pro-

cess-variables impact using Box-Behnken based statistical design.

Int J Biol Macromol 2017; 104(Pt A): 758-67.

http://dx.doi.org/10.1016/j.ijbiomac.2017.05.129 PMID: 28601649

[41] Alam MS, Javed MN, Pottoo FH, et al. QbD approached comparison

of reaction mechanism in microwave synthesized gold nanoparticles

and their superior catalytic role against hazardous nirto‐dye. Appl

Organomet Chem 2019; 33(9): e5071.

http://dx.doi.org/10.1002/aoc.5071

[42] Javed MN, Pottoo FH, Alam MS. Metallic nanoparticle alone and/or

in combination as novel agent for the treatment of uncontrolled elec-

tric conductance related disorders and/or seizure, epilepsy & convul-

sions. WO Patent 2017060916A1, 2016.

[43] Pandit J, Alam MS, Ansari JR, et al. Multifaced applications of na-

noparticles in biological science. In: Nanomaterials in the Battle

Against Pathogens and Disease Vectors. CRC Press 2022; pp. 17-50.

http://dx.doi.org/10.1201/9781003126256-2

[44] Alam MS, Naseh MF, Ansari JR, et al. 3 Synthesis Approaches. In:

Nanomaterials in the Battle Against Pathogens and Disease Vectors.

2022; p. 51.

[45] Di Pietro P, Strano G, Zuccarello L, Satriano C. Gold and silver na-

noparticles for applications in theranostics. Curr Top Med Chem

2016; 16(27): 3069-102.

http://dx.doi.org/10.2174/1568026616666160715163346

PMID: 27426869

[46] Liang JJ, Zhou YY, Wu J, Ding Y. Gold nanoparticle-based drug de-

livery platform for antineoplastic chemotherapy. Curr Drug Metab

2014; 15(6): 620-31.

http://dx.doi.org/10.2174/1389200215666140605131427 PMID:

24909418

[47] Khafaji M, Zamani M, Golizadeh M, Bavi O. Inorganic nanomateri-

als for chemo/photothermal therapy: a promising horizon on effec-

tive cancer treatment. Biophys Rev 2019; 11(3): 335-52.

http://dx.doi.org/10.1007/s12551-019-00532-3 PMID: 31102198

[48] Hauser AK, Mitov MI, Daley EF, McGarry RC, Anderson KW, Hilt

JZ. Targeted iron oxide nanoparticles for the enhancement of radia-

tion therapy. Biomaterials 2016; 105: 127-35.

http://dx.doi.org/10.1016/j.biomaterials.2016.07.032

PMID: 27521615

[49] Jayagopal A, Su YR, Blakemore JL, Linton MF, Fazio S, Haselton

FR. Quantum dot mediated imaging of atherosclerosis. Nanotechnol-

ogy 2009; 20(16): 165102.

http://dx.doi.org/10.1088/0957-4484/20/16/165102

PMID: 19420562

[50] Wei H, Bruns OT, Kaul MG, et al. Exceedingly small iron oxide na-

noparticles as positive MRI contrast agents. Proc Natl Acad Sci USA

2017; 114(9): 2325-30.

http://dx.doi.org/10.1073/pnas.1620145114 PMID: 28193901

[51] Su X, Chan C, Shi J, et al. A graphene quantum dot@Fe 3 O 4 @SiO

2 based nanoprobe for drug delivery sensing and dual-modal fluores-

cence and MRI imaging in cancer cells. Biosens Bioelectron 2017;

92: 489-95.

http://dx.doi.org/10.1016/j.bios.2016.10.076 PMID: 27839733

[52] Wang W, Sun X, Zhang H, et al. Controlled release hydrogen sulfide

delivery system based on mesoporous silica nanoparticles protects

graft endothelium from ischemia-reperfusion injury. Int J Nanomed-

icine 2016; 11: 3255-63.

http://dx.doi.org/10.2147/IJN.S104604 PMID: 27486324

[53] Perioli L, Pagano C, Ceccarini MR. Current highlights about the

safety of inorganic nanomaterials in healthcare. Curr Med Chem

2019; 26(12): 2147-65.

http://dx.doi.org/10.2174/0929867325666180723121804

PMID: 30033865

[54] Mishra S, Sharma S, Javed MN, et al. Bioinspired nanocomposites:

applications in disease diagnosis and treatment. Pharm Nanotechnol

2019; 7(3): 206-19.

http://dx.doi.org/10.2174/2211738507666190425121509

PMID: 31030662

[55] Javed MN, Alam MS, Waziri A, et al. QbD applications for the de-

velopment of nanopharmaceutical products. In: Pharmaceutical qual-

ity by design. Academic Press 2019; pp. 229-53.

http://dx.doi.org/10.1016/B978-0-12-815799-2.00013-7

[56] Bertrand N, Leroux JC. The journey of a drug-carrier in the body: An

anatomo-physiological perspective. J Control Release 2012; 161(2):

152-63.

http://dx.doi.org/10.1016/j.jconrel.2011.09.098 PMID: 22001607

[57] Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of

synergistic drug combinations for cancer therapy - Strategies and

perspectives. J Control Release 2016; 240: 489-503.

http://dx.doi.org/10.1016/j.jconrel.2016.06.012 PMID: 27287891

[58] Wong CH, Siah KW, Lo AW. Estimation of clinical trial success

rates and related parameters. Biostatistics 2019; 20(2): 273-86.

http://dx.doi.org/10.1093/biostatistics/kxx069 PMID: 29394327

[59] Farokhzad OC, Langer R. Impact of nanotechnology on drug deliv-

ery. ACS Nano 2009; 3(1): 16-20.

http://dx.doi.org/10.1021/nn900002m PMID: 19206243

[60] Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer nanomed-

icine: from targeted delivery to combination therapy. Trends Mol

Med 2015; 21(4): 223-32.

http://dx.doi.org/10.1016/j.molmed.2015.01.001 PMID: 25656384

[61] Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Na-

nomedicine 2015; 10: 975-99.

http://dx.doi.org/10.2147/IJN.S68861 PMID: 25678787

[62] Liang R, Wei M, Evans DG, Duan X. Inorganic nanomaterials for

bioimaging, targeted drug delivery and therapeutics. Chem Commun

(Camb) 2014; 50(91): 14071-81.

http://dx.doi.org/10.1039/C4CC03118K PMID: 24955443

[63] Englert C, Brendel JC, Majdanski TC, et al. Pharmapolymers in the

21st century: Synthetic polymers in drug delivery applications. Prog

Polym Sci 2018; 87: 107-64.

http://dx.doi.org/10.1016/j.progpolymsci.2018.07.005

[64] Taresco V, Alexander C, Singh N, Pearce AK. Stimuli‐responsive

prodrug chemistries for drug delivery. Adv Ther 2018; 1(4):

1800030.

http://dx.doi.org/10.1002/adtp.201800030

Role of Nanomedicine for Targeted Pharmaceutical Nanotechnology, xxxx, Vol. xx, No. x 15

[65] Rampaka R, Ommi K, Chella N. Role of solid lipid nanoparticles as

drug delivery vehicles on the pharmacokinetic variability of Erlotinib

HCl. J Drug Deliv Sci Technol 2021; 66: 102886.

http://dx.doi.org/10.1016/j.jddst.2021.102886

[66] La-Beck NM, Liu X, Wood LM. Harnessing liposome interactions

with the immune system for the next breakthrough in cancer drug

delivery. Front Pharmacol 2019; 10: 220.

http://dx.doi.org/10.3389/fphar.2019.00220 PMID: 30914953

[67] Indoria S, Singh V, Hsieh MF. Recent advances in theranostic poly-

meric nanoparticles for cancer treatment: A review. Int J Pharm

2020; 582: 119314.

http://dx.doi.org/10.1016/j.ijpharm.2020.119314 PMID: 32283197

[68] Thapa RK, Ku SK, Choi HG, Yong CS, Byeon JH, Kim JO. Vibrat-

ing droplet generation to assemble zwitterion-coated gold-graphene

oxide stealth nanovesicles for effective pancreatic cancer chemo-

phototherapy. Nanoscale 2018; 10(4): 1742-9.

http://dx.doi.org/10.1039/C7NR07603G PMID: 29308494

[69] Rozalen M, Sánchez-Polo M, Fernández-Perales M, Widmann TJ,

Rivera-Utrilla J. Synthesis of controlled-size silver nanoparticles for

the administration of methotrexate drug and its activity in colon and

lung cancer cells. RSC Adv 2020; 10(18): 10646-60.

http://dx.doi.org/10.1039/C9RA08657A PMID: 35492913

[70] Halevas EG, Pantazaki AA. Copper nanoparticles as therapeutic an-

ticancer agents. Nanomed Nanotechnol J 2018; 2(1): 119-39.

[71] Dutta SD, Ganguly K, Bandi R, Alle M. A new era of cancer treat-

ment: Carbon nanotubes as drug delivery tools. In: Smart Nano-

materials in Biomedical Applications. Cham: Springer International

Publishing 2022; pp. 155-71.

[72] Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle deliv-

ery to tumours. Nat Rev Mater 2016; 1(5): 16014.

http://dx.doi.org/10.1038/natrevmats.2016.14

[73] Hrubý M, Filippov SK, Štěpánek P. Smart polymers in drug delivery

systems on crossroads: Which way deserves following? Eur Polym J

2015; 65: 82-97.

http://dx.doi.org/10.1016/j.eurpolymj.2015.01.016

[74] Javed MN, Dahiya ES, Ibrahim AM, Alam MS, Khan FA, Pottoo

FH. Recent advancement in clinical application of nanotechnological

approached targeted delivery of herbal drugs. In: Beg S, Barkat M,

Ahmad F, Eds. Nanophytomedicine. Singapore: Springer 2020.

http://dx.doi.org/10.1007/978-981-15-4909-0_9

[75] Javed MN, Pottoo FH, Shamim A, Hasnain MS, Alam MS. Design

of experiments for the development of nanoparticles, nanomaterials,

and nanocomposites. In: Design of Experiments for Pharmaceutical

Product Development: Volume II: Applications and Practical Case

studies. 2021; pp. 151-69.

http://dx.doi.org/10.1007/978-981-33-4351-1_9

[76] Kopeček J, Yang J. Hydrogels as smart biomaterials. Polym Int 2007;

56(9): 1078-98.

http://dx.doi.org/10.1002/pi.2253

[77] Lee BK, Yun YH, Park K. Smart nanoparticles for drug delivery:

Boundaries and opportunities. Chem Eng Sci 2015; 125: 158-64.

http://dx.doi.org/10.1016/j.ces.2014.06.042 PMID: 25684780

[78] Bamrungsap S, Zhao Z, Chen T, et al. Nanotechnology in therapeu-

tics: A focus on nanoparticles as a drug delivery system. Nanomedi-

cine 2012; 7(8): 1253-71.

http://dx.doi.org/10.2217/nnm.12.87 PMID: 22931450

[79] Allen TM, Cullis PR. Liposomal drug delivery systems: From con-

cept to clinical applications. Adv Drug Deliv Rev 2013; 65(1): 36-

48.

http://dx.doi.org/10.1016/j.addr.2012.09.037 PMID: 23036225

[80] Couvreur P. Nanoparticles in drug delivery: Past, present and future.

Adv Drug Deliv Rev 2013; 65(1): 21-3.

http://dx.doi.org/10.1016/j.addr.2012.04.010 PMID: 22580334

[81] Alvarez-Lorenzo C, Concheiro A. Smart drug delivery systems:

From fundamentals to the clinic. Chem Commun 2014; 50(58):

7743-65.

http://dx.doi.org/10.1039/C4CC01429D PMID: 24805962

[82] Crommelin DJA, Florence AT. Towards more effective advanced

drug delivery systems1. Int J Pharm 2013; 454(1): 496-511.

http://dx.doi.org/10.1016/j.ijpharm.2013.02.020 PMID: 23415662

[83] Holzapfel BM, Reichert JC, Schantz JT, et al. How smart do bio-

materials need to be? A translational science and clinical point of

view. Adv Drug Deliv Rev 2013; 65(4): 581-603.

http://dx.doi.org/10.1016/j.addr.2012.07.009 PMID: 22820527

[84] Grund S, Bauer M, Fischer D. Polymers in drug delivery—state of

the art and future trends. Adv Eng Mater 2011; 13(3): B61-87.

http://dx.doi.org/10.1002/adem.201080088

[85] Annabi N, Tamayol A, Uquillas JA, et al. 25th anniversary article:

Rational design and applications of hydrogels in regenerative medi-

cine. Adv Mater 2014; 26(1): 85-124.

http://dx.doi.org/10.1002/adma.201303233 PMID: 24741694

[86] Chang HI, Yeh MK. Clinical development of liposome-based drugs:

formulation, characterization, and therapeutic efficacy. Int J Nano-

medicine 2012; 7: 49-60.

PMID: 22275822

[87] Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanopar-

ticles based drug delivery systems. Colloids Surf B Biointerfaces

2010; 75(1): 1-18.

http://dx.doi.org/10.1016/j.colsurfb.2009.09.001 PMID: 19782542

[88] Rossi F, Ferrari R, Castiglione F, Mele A, Perale G, Moscatelli D.

Polymer hydrogel functionalized with biodegradable nanoparticles

as composite system for controlled drug delivery. Nanotechnology

2015; 26(1): 015602.

http://dx.doi.org/10.1088/0957-4484/26/1/015602 PMID: 25490351

[89] Shimoni O, Postma A, Yan Y, et al. Macromolecule functionaliza-

tion of disulfide-bonded polymer hydrogel capsules and cancer cell

targeting. ACS Nano 2012; 6(2): 1463-72.

http://dx.doi.org/10.1021/nn204319b PMID: 22260171

[90] Stumpel JE, Gil ER, Spoelstra AB, Bastiaansen CWM, Broer DJ,

Schenning APHJ. Stimuli‐responsive materials based on interpene-

trating polymer liquid crystal hydrogels. Adv Funct Mater 2015;

25(22): 3314-20.

http://dx.doi.org/10.1002/adfm.201500745

[91] INHALERS DP. Committee for Proprietary Medicinal Products.

CPMP 1998.

[92] Sander VA, Sánchez López EF, Mendoza Morales L, Ramos Duarte

VA, Corigliano MG, Clemente M. Use of veterinary vaccines for

livestock as a strategy to control foodborne parasitic diseases. Front

Cell Infect Microbiol 2020; 10: 288.

http://dx.doi.org/10.3389/fcimb.2020.00288 PMID: 32670892

[93] Rousseau A, La Carbona S, Dumètre A, et al. Assessing viability and

infectivity of foodborne and waterborne stages (cysts/oocysts) of Gi-

ardia duodenalis, Cryptosporidium spp., and Toxoplasma gondii : a

review of methods. Parasite 2018; 25: 14.

http://dx.doi.org/10.1051/parasite/2018009 PMID: 29553366

[94] Fegan N, Jenson I. The role of meat in foodborne disease: Is there a

coming revolution in risk assessment and management? Meat Sci

2018; 144: 22-9.

http://dx.doi.org/10.1016/j.meatsci.2018.04.018 PMID: 29716760

[95] Flühmann B, Ntai I, Borchard G, Simoens S, Mühlebach S. Nano-

medicines: The magic bullets reaching their target? Eur J Pharm Sci

2019; 128: 73-80.

http://dx.doi.org/10.1016/j.ejps.2018.11.019 PMID: 30465818

[96] Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery sys-

tems: Recent developments and future prospects. J Nanobiotechnol-

ogy 2018; 16(1): 71.

http://dx.doi.org/10.1186/s12951-018-0392-8 PMID: 30231877

[97] Kupferschmidt K, Cohen J. Race to find COVID-19 treatments ac-

celerates. Science 2020; 367(6485): 1412-3.

http://dx.doi.org/10.1126/science.367.6485.1412

[98] Brandhonneur N, Chevanne F, Vié V, et al. Specific and non-specific

phagocytosis of ligand-grafted PLGA microspheres by macrophages.

Eur J Pharm Sci 2009; 36(4-5): 474-85.

http://dx.doi.org/10.1016/j.ejps.2008.11.013 PMID: 19110055

[99] Gomes AJ, Lunardi CN, Caetano FH, Lunardi LO, Machado AEH.

Phagocytosis of PLGA microparticles in rat peritoneal exudate cells:

A time-dependent study. Microsc Microanal 2006; 12(5): 399-405.

http://dx.doi.org/10.1017/S1431927606060284 PMID: 16984666

[100] Torchilin V. Multifunctional nanocarriers. Adv Drug Deliv Rev

2006; 58(14): 1532-55.

http://dx.doi.org/10.1016/j.addr.2006.09.009 PMID: 17092599

[101] Danhier F. To exploit the tumor microenvironment: Since the EPR

effect fails in the clinic, what is the future of nanomedicine? J Control

Release 2016; 244(Pt A): 108-21.

http://dx.doi.org/10.1016/j.jconrel.2016.11.015 PMID: 27871992

[102] Padera TP, Stoll BR, Tooredman JB, Capen D, Tomaso E, Jain RK.

Cancer cells compress intratumour vessels. Nature 2004; 427(6976):

695-5.

16 Pharmaceutical Nanotechnology, xxxx, Vol. x, No. x Hooda et al.

http://dx.doi.org/10.1038/427695a PMID: 14973470

[103] Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors.

Nat Rev Clin Oncol 2010; 7(11): 653-64.

http://dx.doi.org/10.1038/nrclinonc.2010.139 PMID: 20838415

[104] Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to

tumors: Principles, pitfalls and (pre-) clinical progress. J Control Re-

lease 2012; 161(2): 175-87.

http://dx.doi.org/10.1016/j.jconrel.2011.09.063 PMID: 21945285

[105] Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Chal-

lenges and strategies in anti-cancer nanomedicine development: An

industry perspective. Adv Drug Deliv Rev 2017; 108: 25-38.

http://dx.doi.org/10.1016/j.addr.2016.04.025 PMID: 27137110

[106] Accomasso L, Cristallini C, Giachino C. Risk assessment and risk

minimization in nanomedicine: A need for predictive, alternative,

and 3Rs strategies. Front Pharmacol 2018; 9: 228.

http://dx.doi.org/10.3389/fphar.2018.00228 PMID: 29662451

[107] Petros RA, DeSimone JM. Strategies in the design of nanoparticles

for therapeutic applications. Nat Rev Drug Discov 2010; 9(8): 615-

27.

http://dx.doi.org/10.1038/nrd2591 PMID: 20616808

[108] Ragelle H, Danhier F, Préat V, Langer R, Anderson DG. Nanoparti-

cle-based drug delivery systems: A commercial and regulatory out-

look as the field matures. Expert Opin Drug Deliv 2017; 14(7): 851-

64.

http://dx.doi.org/10.1080/17425247.2016.1244187

PMID: 27730820

[109] Jain MM, Patil S, Pathak AB, et al. The efficacy and safety of

paclitaxel injection concentrate for nano-dispersion (PICN) at two

different doses versus paclitaxel albumin-stabilized nanoparticle for-

mulation in subjects with metastatic breast cancer (MBC). J Clin On-

col 2014; 32(15_suppl): 1069-9.

http://dx.doi.org/10.1200/jco.2014.32.15_suppl.1069

[110] O’Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and

comparable efficacy in a phase IIItrial of pegylated liposomal doxo-

rubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin

forfirst-line treatment of metastatic breast cancer. Ann Oncol 2004;

15(3): 440-9.

http://dx.doi.org/10.1093/annonc/mdh097 PMID: 14998846

[111] Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100

nm polymeric micelles in poorly permeable tumours depends on size.

Nat Nanotechnol 2011; 6(12): 815-23.

http://dx.doi.org/10.1038/nnano.2011.166 PMID: 22020122

[112] Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size,

shape, and surface chemistry on biological systems. Annu Rev Bio-

med Eng 2012; 14(1): 1-16.

http://dx.doi.org/10.1146/annurev-bioeng-071811-150124

PMID: 22524388

[113] Sun X, Rossin R, Turner JL, et al. An assessment of the effects of

shell cross-linked nanoparticle size, core composition, and surface

PEGylation on in vivo biodistribution. Biomacromolecules 2005;

6(5): 2541-54.

http://dx.doi.org/10.1021/bm050260e PMID: 16153091

[114] Peer D. Harnessing RNAi nanomedicine for precision therapy. Mol

Cell Ther 2014; 2(1): 5.

http://dx.doi.org/10.1186/2052-8426-2-5 PMID: 26056574

[115] Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and

clinical translation of a PSMA-targeted docetaxel nanoparticle with

a differentiated pharmacological profile. Sci Transl Med 2012;

4(128): 128ra39.

http://dx.doi.org/10.1126/scitranslmed.3003651 PMID: 22491949

[116] Raza K, Kumar P, Kumar N, Malik R. Pharmacokinetics and biodis-

tribution of the nanoparticles. In: Advances in nanomedicine for the

delivery of therapeutic nucleic acids. Woodhead publishing 2017; pp.

165-86.

http://dx.doi.org/10.1016/B978-0-08-100557-6.00009-2

[117] Soo Choi H, Liu W, Misra P, et al. Renal clearance of quantum dots.

Nat Biotechnol 2007; 25(10): 1165-70.

http://dx.doi.org/10.1038/nbt1340 PMID: 17891134

[118] Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. In vivo tumor

targeting of tumor necrosis factor-α-loaded stealth nanoparticles: Ef-

fect of MePEG molecular weight and particle size. Eur J Pharm Sci

2006; 27(1): 27-36.

http://dx.doi.org/10.1016/j.ejps.2005.08.002 PMID: 16150582

[119] Bertrand N, Grenier P, Mahmoudi M, et al. Mechanistic understand-

ing of in vivo protein corona formation on polymeric nanoparticles

and impact on pharmacokinetics. Nat Commun 2017; 8(1): 777.

http://dx.doi.org/10.1038/s41467-017-00600-w PMID: 28974673

[120] Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-

circulating poly(ethylene glycol)-poly(d,l-lactide) block copolymer

micelles with modulated surface charge. J Control Release 2001;

77(1-2): 27-38.

http://dx.doi.org/10.1016/S0168-3659(01)00451-5

PMID: 11689257

[121] van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modi-

fied Nanocarriers for Tumor-targeted and Intracellular Delivery.

Pharm Res 2007; 24(8): 1405-14.

http://dx.doi.org/10.1007/s11095-007-9284-6 PMID: 17393074

[122] Bertholon I, Vauthier C, Labarre D. Complement activation by core-

shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: in-

fluences of surface morphology, length, and type of polysaccharide.

Pharm Res 2006; 23(6): 1313-23.

http://dx.doi.org/10.1007/s11095-006-0069-0 PMID: 16715369

[123] Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and

particle size on the cellular uptake efficiency of nanoparticles with

the HepG2 cells. J Control Release 2007; 118(1): 7-17.

http://dx.doi.org/10.1016/j.jconrel.2006.11.028 PMID: 17241684

[124] Musyanovych A, Dausend J, Dass M, Walther P, Mailänder V, Land-

fester K. Criteria impacting the cellular uptake of nanoparticles: A

study emphasizing polymer type and surfactant effects. Acta Bio-

mater 2011; 7(12): 4160-8.

http://dx.doi.org/10.1016/j.actbio.2011.07.033 PMID: 21855659

[125] Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent inter-

nalization of particles via the pathways of clathrin- and caveolae-me-

diated endocytosis. Biochem J 2004; 377(1): 159-69.

http://dx.doi.org/10.1042/bj20031253 PMID: 14505488

[126] Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size

on in vivo pharmacokinetics and cellular interaction. Nanomedicine

(Lond) 2016; 11(6): 673-92.

http://dx.doi.org/10.2217/nnm.16.5 PMID: 27003448

[127] Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for

overcoming biological barriers to drug delivery. Nat Biotechnol

2015; 33(9): 941-51.

http://dx.doi.org/10.1038/nbt.3330 PMID: 26348965

[128] Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of

tumor-specific targeting on the biodistribution and efficacy of siRNA

nanoparticles measured by multimodality in vivo imaging. Proc Natl

Acad Sci USA 2007; 104(39): 15549-54.

http://dx.doi.org/10.1073/pnas.0707461104 PMID: 17875985

[129] Matsumura Y, Maeda H. A new concept for macromolecular thera-

peutics in cancer chemotherapy: mechanism of tumoritropic accumu-

lation of proteins and the antitumor agent smancs. Cancer Res 1986;

46(12 Pt 1): 6387-92.

PMID: 2946403

[130] Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of

tumor blood vessels for drug delivery, factors involved, and limita-

tions and augmentation of the effect. Adv Drug Deliv Rev 2011;

63(3): 136-51.

http://dx.doi.org/10.1016/j.addr.2010.04.009 PMID: 20441782

[131] Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100

years of progress. Nat Rev Cancer 2008; 8(6): 473-80.

http://dx.doi.org/10.1038/nrc2394 PMID: 18469827

[132] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparti-

cle-based medicines: a review of FDA-approved materials and clini-

cal trials to date. Pharm Res 2016; 33(10): 2373-87.

http://dx.doi.org/10.1007/s11095-016-1958-5 PMID: 27299311

[133] Duncan R. Polymer therapeutics: Top 10 selling pharmaceuticals —

What next? J Control Release 2014; 190: 371-80.

http://dx.doi.org/10.1016/j.jconrel.2014.05.001 PMID: 24818766

[134] Ventola CL. Progress in nanomedicine: approved and investigational

nanodrugs. P&T 2017; 42(12): 742-55.

PMID: 29234213

[135] Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nano-

technology: The impact of passive and active targeting in the era of

modern cancer biology. Adv Drug Deliv Rev 2014; 66: 2-25.

http://dx.doi.org/10.1016/j.addr.2013.11.009 PMID: 24270007

Role of Nanomedicine for Targeted Pharmaceutical Nanotechnology, xxxx, Vol. xx, No. x 17

[136] Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting

schemes for nanoparticle systems in cancer therapeutics. Adv Drug

Deliv Rev 2008; 60(15): 1615-26.

http://dx.doi.org/10.1016/j.addr.2008.08.005 PMID: 18840489

[137] Karmali PP, Kotamraju VR, Kastantin M, et al. Targeting of albu-

min-embedded paclitaxel nanoparticles to tumors. Nanomedicine

2009; 5(1): 73-82.

http://dx.doi.org/10.1016/j.nano.2008.07.007 PMID: 18829396

[138] Marcucci F, Lefoulon F. Active targeting with particulate drug carri-

ers in tumor therapy: fundamentals and recent progress. Drug Discov

Today 2004; 9(5): 219-28.

http://dx.doi.org/10.1016/S1359-6446(03)02988-X

PMID: 14980540

[139] Maruyama K. PEG-Immunoliposome. Biosci Rep 2002; 22(2): 251-

66.

http://dx.doi.org/10.1023/A:1020138622686 PMID: 12428903

[140] Toporkiewicz M, Meissner J, Matusewicz L, Czogalla A, Sikorski

AF. Toward a magic or imaginary bullet? Ligands for drug targeting

to cancer cells: principles, hopes, and challenges. Int J Nanomedicine

2015; 10: 1399-414.

PMID: 25733832

[141] Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat

Rev Cancer 2002; 2(10): 750-63.

http://dx.doi.org/10.1038/nrc903 PMID: 12360278

[142] Prabhakar U, Maeda H, Jain RK, et al. Challenges and key consider-

ations of the enhanced permeability and retention effect for nano-

medicine drug delivery in oncology. Cancer Res 2013; 73(8): 2412-

http://dx.doi.org/10.1158/0008-5472.CAN-12-4561

PMID: 23423979

[143] Lammers T, Rizzo LY, Storm G, Kiessling F. Personalized Nano-

medicine. Clin Cancer Res 2012; 18(18): 4889-94.

http://dx.doi.org/10.1158/1078-0432.CCR-12-1414

PMID: 22829203

[144] Natfji AA, Ravishankar D, Osborn HMI, Greco F. Parameters affect-

ing the enhanced permeability and retention effect: the need for pa-

tient selection. J Pharm Sci 2017; 106(11): 3179-87.

http://dx.doi.org/10.1016/j.xphs.2017.06.019 PMID: 28669714

[145] Gregoriadis G, Swain CP, Wills EJ, Tavill AS. Drug-carrier potential

of liposomes in cancer chemotherapy. Lancet 1974; 303(7870):

1313-6.

http://dx.doi.org/10.1016/S0140-6736(74)90682-5 PMID: 4134296

[146] Segal AW, Gregoriadis G, Lavender JP, Tarin D, Peters TJ. Tissue

and hepatic subcellular distribution of liposomes containing bleomy-

cin after intravenous administration to patients with neoplasms. Clin

Sci Mol Med 1976; 51(4): 421-5.

http://dx.doi.org/10.1042/cs0510421 PMID: 61088

[147] Richardson VJ, Ryman BE, Jewkes RF, et al. Tissue distribution and

tumour localization of 99m-technetium-labelled liposomes in cancer

patients. Br J Cancer 1979; 40(1): 35-43.

http://dx.doi.org/10.1038/bjc.1979.138 PMID: 475960

[148] Perez-Soler R, Lopez-Berestein G, Kasi LP, et al. Distribution of

technetium-99m-labeled multilamellar liposomes in patients with

Hodgkin’s disease. J Nucl Med 1985; 26(7): 743-9.

PMID: 3925093

[149] Lopez-Berestein G, Kasi L, Rosenblum MG, et al. Clinical pharma-

cology of 99mTc-labeled liposomes in patients with cancer. Cancer

Res 1984; 44(1): 375-8.

PMID: 6317172

[150] Turner AF, Presant CA, Proffitt RT, Williams LE, Winsor DW, Wer-

ner JL. In-111-labeled liposomes: dosimetry and tumor depiction.

Radiology 1988; 166(3): 761-5.

http://dx.doi.org/10.1148/radiology.166.3.3340774 PMID: 3340774

[151] Presant CA, Proffitt RT, Turner AF, et al. Successful imaging of hu-

man cancer with indium-111-labeled phospholipid vesicles. Cancer

1988; 62(5): 905-11.

http://dx.doi.org/10.1002/1097-0142(19880901)62:5<905::AID-

CNCR2820620509>3.0.CO;2-3 PMID: 3409173

[152] Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for mo-

lecular imaging and therapy. Curr Probl Cardiol 2003; 28(12): 625-

53.

http://dx.doi.org/10.1016/j.cpcardiol.2003.11.001 PMID: 14691443

[153] Wickline SA, Lanza GM. Nanotechnology for molecular imaging

and targeted therapy. Circulation 2003; 107(8): 1092-5.

http://dx.doi.org/10.1161/01.CIR.0000059651.17045.77

PMID: 12615782

[154] Flacke S, Fischer S, Scott MJ, et al. Novel MRI contrast agent for

molecular imaging of fibrin: implications for detecting vulnerable

plaques. Circulation 2001; 104(11): 1280-5.

http://dx.doi.org/10.1161/hc3601.094303 PMID: 11551880

[155] Frank JA, Miller BR, Arbab AS, et al. Clinically applicable labeling

of mammalian and stem cells by combining superparamagnetic iron

oxides and transfection agents. Radiology 2003; 228(2): 480-7.

http://dx.doi.org/10.1148/radiol.2281020638 PMID: 12819345

[156] Kraitchman DL, Heldman AW, Atalar E, et al. in vivo magnetic res-

onance imaging of mesenchymal stem cells in myocardial infarction.

Circulation 2003; 107(18): 2290-3.

http://dx.doi.org/10.1161/01.CIR.0000070931.62772.4E

PMID: 12732608

[157] Nikalje AP. Nanotechnology and its applications in medicine. Med

chem 2015; 5(2): 081-9.

http://dx.doi.org/10.4172/2161-0444.1000247

[158] Thiruppathi R, Mishra S, Ganapathy M, Padmanabhan P, Gulyás B.

Nanoparticle functionalization and its potentials for molecular imag-

ing. Adv Sci (Weinh) 2017; 4(3): 1600279.

http://dx.doi.org/10.1002/advs.201600279 PMID: 28331783

[159] Iacono P, Karabeber H, Kircher MF. A “schizophotonic” all-in-one

nanoparticle coating for multiplexed SE(R)RS biomedical imaging.

Angew Chem Int Ed 2014; 53(44): 11756-61.

http://dx.doi.org/10.1002/anie.201403835 PMID: 25164141

[160] Muthukumar T, Chamundeeswari M, Prabhavathi S, Gurunathan B,

Chandhuru J, Sastry TP. Carbon nanoparticle from a natural source

fabricated for folate receptor targeting, imaging and drug delivery

application in A549 lung cancer cells. Eur J Pharm Biopharm 2014;

88(3): 730-6.

http://dx.doi.org/10.1016/j.ejpb.2014.09.011 PMID: 25305584

[161] Ghaghada KB, Badea CT, Karumbaiah L, et al. Evaluation of tumor

microenvironment in an animal model using a nanoparticle contrast

agent in computed tomography imaging. Acad Radiol 2011; 18(1):

20-30.

http://dx.doi.org/10.1016/j.acra.2010.09.003 PMID: 21145026

[162] Hainfeld JF, Smilowitz HM, O’Connor MJ, Dilmanian FA, Slatkin

DN. Gold nanoparticle imaging and radiotherapy of brain tumors in

mice. Nanomedicine (Lond) 2013; 8(10): 1601-9.

http://dx.doi.org/10.2217/nnm.12.165 PMID: 23265347

[163] Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT

imaging of macrophages in inflammatory atherosclerosis. Circula-

tion 2008; 117(3): 379-87.

http://dx.doi.org/10.1161/CIRCULATIONAHA.107.741181 PMID:

18158358

[164] Wong HL, Wu XY, Bendayan R. Nanotechnological advances for

the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64(7):

686-700.

http://dx.doi.org/10.1016/j.addr.2011.10.007 PMID: 22100125

[165] Pottoo FH, Sharma S, Javed MN, et al. Lipid-based nanoformula-

tions in the treatment of neurological disorders. Drug Metab Rev

2020; 52(1): 185-204.

http://dx.doi.org/10.1080/03602532.2020.1726942

PMID: 32116044

[166] Ibrahim AM, Chauhan L, Bhardwaj A, et al. Brain-derived neuro-

tropic factor in neurodegenerative disorders. Biomedicines 2022;

10(5): 1143.

http://dx.doi.org/10.3390/biomedicines10051143 PMID: 35625880

[167] Aslam M, Javed MN, Deeb HH, et al. Lipid carriers mediated tar-

geted delivery of nutraceuticals: Challenges, role of blood brain bar-

rier and promises of nanotechnology based ap-proaches in neuronal

disorders. Curr Drug Metab 2020; 21: 21.

http://dx.doi.org/10.2174/1389200221999200728143511

[168] Javed MN, Akhter MH, Taleuzzaman M, Faiyazudin M, Alam MS.

Cationic nanoparticles for treatment of neurological diseases. In:

Fundamentals of Bionanomaterials. Elsevier 2022; pp. 273-92.

http://dx.doi.org/10.1016/B978-0-12-824147-9.00010-8

[169] Kumari N, Daram N, Alam MS, Verma AK. Rationalizing the use of

polyphenol nano-formulations in the therapy of neurodegenerative

diseases. CNS Neurol Disord Drug Targets 2022; 21(10): 966-76.

18 Pharmaceutical Nanotechnology, xxxx, Vol. x, No. x Hooda et al.

[170] Pottoo FH, Tabassum N, Javed MN, et al. The synergistic effect of

raloxifene, fluoxetine, and bromocriptine protects against pilocar-

pine-induced status epilepticus and temporal lobe epilepsy. Mol Neu-

robiol 2019; 56(2): 1233-47.

http://dx.doi.org/10.1007/s12035-018-1121-x PMID: 29881945

[171] Pottoo FH, Javed MN, Barkat MA, et al. Estrogen and serotonin:

complexity of interactions and implications for epileptic seizures and

epileptogenesis. Curr Neuropharmacol 2019; 17(3): 214-31.

http://dx.doi.org/10.2174/1570159X16666180628164432

PMID: 29956631

[172] Pottoo FH, Tabassum N, Javed MN, et al. Raloxifene potentiates the

effect of fluoxetine against maximal electroshock induced seizures

in mice. Eur J Pharm Sci 2020; 146: 105261.

http://dx.doi.org/10.1016/j.ejps.2020.105261

PMID: 32061655

[173] Chiu SS, Terpstra K, Woodbury-Farina M, et al. Transforming curry

extract to liposomal curcumin (LipocurcTM) in Parkinson disease

(PD) therapeutics landscape: Emerging role of epigenetics signaling

and nanotechnology. EC Neurology 2020; 12(2): 01-12.

[174] Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. Lactoferrin conju-

gated PEG-PLGA nanoparticles for brain delivery: Preparation, char-

acterization and efficacy in Parkinson’s disease. Int J Pharm 2011;

415(1-2): 273-83.

http://dx.doi.org/10.1016/j.ijpharm.2011.05.062

PMID: 21651967

[175] Ko WC, Wang SJ, Hsiao CY, et al. Pharmacological role of func-

tionalized gold nanoparticles in disease applications. Molecules

2022; 27(5): 1551.

http://dx.doi.org/10.3390/molecules27051551 PMID: 35268651

[176] Liao X, Ge K, Cai Z, et al. Hybridization chain reaction triggered

poly adenine to absorb silver nanoparticles for label-free electro-

chemical detection of Alzheimer’s disease biomarkers amyloid β-

peptide oligomers. Anal Chim Acta 2022; 1192: 339391.

http://dx.doi.org/10.1016/j.aca.2021.339391 PMID: 35057926

[177] Pohanka M. Copper and copper nanoparticles toxicity and their im-

pact on basic functions in the body. Bratisl Med J 2019; 120(6): 397-

409.

http://dx.doi.org/10.4149/BLL_2019_065 PMID: 31223019

[178] Xiang C, Zhang Y, Guo W, Liang XJ. Biomimetic carbon nanotubes

for neurological disease therapeutics as inherent medication. Acta

Pharm Sin B 2020; 10(2): 239-48.

http://dx.doi.org/10.1016/j.apsb.2019.11.003 PMID: 32082970

[179] Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-

80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to

the CNS via specific mechanisms requiring prior binding of drug to

the nanoparticles. Pharm Res 2003; 20(3): 409-16.

http://dx.doi.org/10.1023/A:1022604120952 PMID: 12669961

[180] Costigan S. The toxicology of nanoparticles used in health care prod-

ucts, Medicines and Healthcare Products. Department of Health

2006.

[181] de Jong . Drug delivery and nanoparticles: Applications and hazards.

Int J Nanomedicine 2008; 133: 133.

http://dx.doi.org/10.2147/IJN.S596

DISCLAIMER: The above article has been published, as is, ahead-of-print, to provide early visibility but is not the final version.

Major publication processes like copyediting, proofing, typesetting and further review are still to be done and may lead to changes

in the final published version, if it is eventually published. All legal disclaimers that apply to the final published article also apply

to this ahead-of-print version.

ResearchGate has not been able to resolve any citations for this publication.

ResearchGate has not been able to resolve any references for this publication.

Role of Nanomedicine for Targeted Drug Delivery in Livestock: Future Prospective

Abstract and Figures

Recommended publications

Leveraging Physiology for Precision Drug Delivery

Organic and Hybrid Nanoparticles for Controlled Instigation of Inertial Cavitation Using Therapeutic...

Pain—novel targets and new technologies

Nanosponges as a biocatalyst carrier — An innovative drug delivery technology for enzymes, proteins,...